UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2024

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____________ to ____________

Commission File Number: 0-56013

JRSIS HEALTH CARE CORPORATION
(Exact name of registrant as specified in its charter)

Florida		46-4562047
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)
Building 2, Youth Innovation and Entrepreneurship Park Xiaoxiang Science and Technology Innovation Center Yongzhou Economic and Technology Development Zone Hunan Province 425000 P.R. China
(Address of Principal Executive Offices) (Zip Code)

+86-760-88963658
(Registrant’s telephone number, including area code)

Not Applicable
(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class		Trading Symbol(s)		Name of Each Exchange on Which Registered
Common stock, $0.0001 par value		Not Applicable		Not Applicable

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such fi les). ☒ Yes ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐	Accelerated filer ☐
Non-accelerated filer ☐	Smaller reporting company ☒
	Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☒ No

As of March 31, 2024, the registrant had 84,598,650 shares of common stock, par value $.0001 per share, issued and outstanding.

TABLE OF CONTENTS

		Page
PART I	FINANCIAN INFORMATION	1
Item 1	Financial Statements	1
Item 2	Management’s Discussion and Analysis of Financial Condition and Results of Operations	29
Item 3	Quantitative and Qualitative Disclosures About Market Risk	35
Item 4	Controls and Procedures	35
PART II	OTHER INFORMATION	36
Item 1	Legal Proceedings	36
Item 1A	Risk Factors	36
Item 2	Unregistered Sales of Equity Securities and Use of Proceeds	36
Item 3	Defaults Upon Senior Securities	36
Item 4	Mine Safety Disclosures	36
Item 5	Other Information.	36
Item 6	Exhibits.	36
Signatures		37

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

JRSIS HEALTH CARE CORPORATION AND ITS SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

	March 31,			December 31,
	2024			2023
	(Unaudited)
ASSETS
CURRENT ASSETS
Cash	$	323,611		$	118,114
Accounts receivable, net		603,022			714,658
Accounts receivable, net - related parties		100,376			121,086
Advances to suppliers		251,404			345,961
Amount due from related parties		2,631			1,620
Inventories		445,500			455,240
Prepayments and other receivables		89,278			77,211
Total Current Assets		1,815,822			1,833,890

NON-CURRENT ASSETS
Equipment and vehicles, net		46,193			50,024
Intangible assets, net		243,897			257,334
Right of use assets		2,161			3,277
Total Non-Current Assets		292,251			310,635
TOTAL ASSETS	$	2,108,073		$	2,144,525

LIABILITIES AND EQUITY
CURRENT LIABILITIES
Short-term loans	$	1,368,261		$	983,007
Long-term loans due within one year		24,534			18,713
Accounts payable, trade		496,793			540,086
Accounts payable, trade-related parties		66,922			261,200
Advances from customers		223,121			218,313
Amount due to related parties		5,665			14,917
Taxes payable		39,552			18,845
Other payables and accrued liabilities		169,938			221,869
Finance lease liabilities, current		-			-
Operating lease liabilities, current		2,161			3,277
Total Current Liabilities		2,396,947			2,280,227

Long-term loans - noncurrent portion		18,401			24,950
Operating lease liabilities, non-current		-			-
TOTAL LIABILITIES		2,415,348			2,305,177

COMMITMENTS AND CONTINGENCIES		-			-

EQUITY

Preferred stock, $0.0001 par value; 2,000,000 shares preferred stock authorized; nil issued and outstanding as of March 31, 2024 and December 31, 2023, respectively		-			-
Common stock, $0.0001 par value; 100,000,000 shares authorized; 84,598,650 and 82,594,105 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively		8,460			8,259
Additional paid-in capital		3,174,217			3,154,373
Statutory reserves		-			-
Accumulated deficit		(3,588,254	)		(3,442,898	)
Accumulated other comprehensive income		145,644			142,860
Total JRSIS HEALTH CARE CORPORATION's equity		(259,933	)		(137,406	)
NONCONTROLLING INTERESTS		(47,342	)		(23,246	)
TOTAL EQUITY		(307,275	)		(160,652	)
TOTAL LIABILITIES AND EQUITY	$	2,108,073		$	2,144,525

The accompanying notes are an integral part of the unaudited consolidated financial statements

JRSIS HEALTH CARE CORPORATION AND ITS SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)

(UNAUDITED)

	For The Three Months Ended March 31,
	2024			2023
REVENUE	$	500,420		$	476,994
COST OF REVENUE		443,198			325,602
GROSS PROFIT		57,222			151,392

OPERATING EXPENSES:
Sales and marketing		106,762			12,341
General and administrative		101,112			31,232
Research and development		10,254			30,295
Total operating expenses		218,128			73,868

INCOME (LOSS) FROM OPERATIONS		(160,906	)		77,524

OTHER INCOME (EXPENSE)
Interest income		67			303
Interest expense		(11,906	)		(19,738	)
Other income (expense)		2,797			3,329
Total other income (expense), net		(9,042	)		(16,106	)

INCOME (LOSS) BEFORE INCOME TAXES		(169,948	)		61,418

PROVISION FOR INCOME TAXES		-			8,283

NET INCOME (LOSS)		(169,948	)		53,135
Less: net income (loss) attributable to noncontrolling interest		(24,592	)		7,689
NET INCOME (LOSS) ATTRIBUTABLE TO JRSIS HEALTH CARE CORPORATION	$	(145,356	)	$	45,446

COMPREHENSIVE INCOME (LOSS)
NET INCOME (LOSS)	$	(169,948	)	$	53,135
OTHER COMPREHENSIVE INCOME (LOSS)
Foreign currency translation adjustment		3,280			(487	)
TOTAL COMPREHENSIVE INCOME (LOSS)		(166,668	)		52,648
Less: comprehensive income (loss) attributable to noncontrolling interest		(24,096	)		7,619
COMPREHENSIVE INCOME (LOSS) ATTRIBUTABLE TO JRSIS HEALTH CARE CORPORATION	$	(142,572	)	$	45,029

WEIGHTED AVERAGE NUMBER OF COMMON SHARES
Basic and diluted		84,334,314			76,757,439

EARNINGS (LOSS) PER SHARE
Net income (loss) - basic and diluted	$	(0.002	)	$	0.001

The accompanying notes are an integral part of the unaudited consolidated financial statements

JRSIS HEALTH CARE CORPORATION AND ITS SUBSIDIARIES

CONSOLIDATED STATEMENTS OF EQUITY

											Accumulated
	Common Stock				Additional						other
	Number of				Paid-in			Retained			comprehensive		Noncontrolling
	Shares		Par Value		capital			earnings			income		interest			Total
BALANCE, January 1, 2023		76,757,439	$	7,676	$	3,154,881		$	(3,361,986	)	$	140,976	$	(9,890	)	$	(68,343	)
Issuance of common shares to acquired accounting acquiree		5,836,666		583		(508	)		-			-		-			75
Net income				-		-			(80,912	)		-		(13,676	)		(94,588	)
Foreign currency translation adjustments				-		-			-			1,884		320			2,204
BALANCE, December 31, 2023		82,594,105		8,259		3,154,373			(3,442,898	)		142,860		(23,246	)		(160,652	)
Issuance of common shares		2,004,545		201		19,844			-			-		-			20,045
Net income				-		-			(145,356	)		-		(24,592	)		(169,948	)
Foreign currency translation adjustments				-		-			-			2,784		496			3,280
BALANCE, March 31, 2024 (Unaudited)		84,598,650	$	8,460	$	3,174,217		$	(3,588,254	)	$	145,644	$	(47,342	)	$	(307,275	)

The accompanying notes are an integral part of the unaudited consolidated financial statements

JRSIS HEALTH CARE CORPORATION AND ITS SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

	For the Three Months Ended March 31,
	2024			2023
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss) from continuing operations	$	(169,948	)	$	53,135
Adjustments to reconcile net income (loss) to cash used in operating activities:
Depreciation and amortization		12,197			14,403
Right-of-use assets amortization		1,066			1,064
Lease liabilities interest expense		25			77
Inventories impairment (return)		(412	)		(6,202	)
Deferred income tax		-			4,613
Change in operating assets and liabilities
Accounts receivable		100,160			246,259
Accounts receivable - related parties		18,773			(144,085	)
Advances to suppliers		89,181			(62,688	)
Inventories		2,571			(145,871	)
Prepayments and other receivables		(13,414	)		(524	)
Accounts payable		(34,439	)		(14,903	)
Accounts payable - related parties		(190,763	)		37,374
Advances from customers		8,486			(3,136	)
Taxes payable		21,115			(12,680	)
Lease liabilities		(1,091	)		(2,287	)
Other payables and accrued liabilities		(48,444	)		18,944
Net cash used in operating activities		(204,937	)		(16,507	)

CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment		-			-
Purchase of intangible assets		-			-
Net cash provided by investing activities		-			-

CASH FLOWS FROM FINANCING ACTIVITIES:
Cash from issuance of common shares		20,045			-
Proceeds from loans		403,422			-
Repayment of short-term loans		-			(166,210	)
Amount financed from (to) related parties		(10,200	)		23,035

Net cash provided by (used in) financing activities		413,267			(143,175	)


EFFECT OF EXCHANGE RATE ON CASH		(2,833	)		5,507

INCREASE (DECREASE) IN CASH		205,497			(154,175	)

CASH AND CASH EQUIVALENTS, beginning of period		118,114			158,813

CASH AND CASH EQUIVALENTS, end of period	$	323,611		$	4,638

SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for income tax	$	957		$	1,447
Cash paid for interest expense, net of capitalized interest	$	11,898		$	16,569
NON-CASH TRANSACTIONS OF INVESTING AND FINANCING ACTIVITIES

The accompanying notes are an integral part of the unaudited consolidated financial statements

JRSIS HEALTH CARE CORPORATION ITS SUBSIDIARIES

NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

ORGANIZATION AND BUSINESS BACKGROUND

JRSIS Health Care Corporation (the “Company” or “JRSIS”) was incorporated on November 20, 2013 under the laws of the State of Florida. In December 2013 JRSIS acquired 100% of the equity in JRSIS Health Care Limited (“JRSIS-BVI”), which is a limited liability company registered in British Virgin Island (“BVI”) on February 25, 2013. JRSIS-BVI owns 100% of the equity in Runteng Medical Group Co., Ltd. (“Runteng”), a limited liability company registered in Hong Kong on September 17, 2012.

Until March 31, 2022, Runteng owned 70% of the equity in Harbin Jiarun Hospital Co., Ltd. (“Jiarun”), a for-profit hospital incorporated in Harbin City of Heilongjiang, the People’s Republic of China in February 2006. The remaining 30% of the equity in Jiarun was owned by Junsheng Zhang, who is the Chairman of the Board of JRSIS Health Care Corporation until March 2022. On April 28, Runteng transferred its 70% equity interest in Jiarun to Zhang Junsheng (the “Spin-Off”). In exchange for the 70% interest in Jiarun, Zhang Junsheng transferred to Runteng 5,392,000 shares of JRSIS common stock. After the Spin-Off, JRSIS does not beneficially own any equity interest in Jiarun and will no longer consolidate Jiarun financial results with the financial results of JRSIS as on April 1, 2022.

On April 12, 2022, Runteng organized and owned 100% of the equity in Laidian Technology (Zhongshan) Co., Ltd. (“Laidian”), a wholly foreign-owned enterprise (“WFOE”) subsidiary registered under the law of the People’s Republic of China (“the PRC”) in Zhongshan City, Guangdong Province. Laidian initially engage in the business of providing charging services to electric vehicles operating in Zhongshan City, until the Company obtained the majority variable interest in Yongzhou Jumi Intelligent Technology Co., Ltd. (“Yongzhou JIT”) on November 30, 2023.

On November 30, 2023, the Company through Laidian, a wholly-owned subsidiary of JRSIS, completed an acquisition transaction by entering into and executing four agreements with Yongzhou Jumi Intelligent Technology Co., Ltd. (“Yongzhou JIT”) and Guangzhou Jumi Intelligent Equipment Co., Ltd. (“Guangzhou JIE”) (the “Management Agreements”). After execution of the Management Agreements, the Company obtained 85.53% variable interest in Yongzhou JIT. Following the transaction, we have abandoned our prior business plan and we are now pursuing Yongzhou JIT’s historical businesses and its proposed businesses.

Each of the Management Agreements is summarized as below:

Exclusive Business Cooperation Agreement.

Under the Exclusive Business Consulting Agreement between Laidian and Yongzhou JIT, Laidian has the exclusive right to provide to Yongzhou JIT marketing, management, consulting and other services related to its business operations. To fulfill its obligations, Laidian will provide to Yongzhou JIT the management and marketing services of Zhuowei Zhong, who is the Chairman of Laidian. In compensation for the services provided by Laidian, Yongzhou JIT will pay Laidian a quarterly fee equal to 85.53% of any net income that Yongzhou JIT earns from its business while being managed by Zhuowei Zhong less any losses carried forward from prior quarters. The remaining 14.47% of the net income earned by Yongzhou JIT will be distributed to Guangzhou JIE for further distribution to an entity that owns 14.47% of Guangzhou JIE and has not agreed to participate in the Management Arrangement (the “14.47% Unpledged Interest”). The Exclusive Business Consulting Agreement will remain in effect until terminated by the parties.

Equity Interest Pledge Agreement.

Guangzhou JIE, which owns all of the registered equity in Yongzhou JIT, has entered into an Equity Interest Pledge Agreement with Laidian. Pursuant to this agreement, Guangzhou JIE pledged 85.53% of its equity interest in Yongzhou JIT, including the right to receive dividends, to Laidian to secure the performance of Yongzhou JIT’s obligations under the Exclusive Business Consulting Agreement described above. If Yongzhou JIT breaches relevant contractual obligations under this agreement, Laidian, as pledgee, will be entitled to certain rights, including the right to sell the pledged equity interests. Guangzhou JIE has agreed not to transfer or create any new encumbrance on its equity interests without the prior written consent of Laidian. The Equity Interest Pledge Agreement shall terminate when Yongzhou JIT has fully performed its obligations under the Exclusive Business Consulting Agreement.

JRSIS HEALTH CARE CORPORATION ITS SUBSIDIARIES

NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

Exclusive Option Agreement.

Under the Exclusive Option Agreement among Laidian, Yongzhou JIT and Guangzhou JIE, Guangzhou JIE irrevocably granted Laidian or its designated person(s) an exclusive option to purchase, when and to the extent permitted under PRC law, all or part of its equity interest in Yongzhou JIT. The purchase price for the equity interest in Yongzhou JIT shall be determined through consultation according to the appraisal value approved by the relevant authorities and shall be the minimum amount permissible under PRC law. The Exclusive Option Agreement will be valid until all of the equity interest in Yongzhou JIT has been transferred to Laidian. The Exclusive Option Agreement provides, among other things, that without Laidian’s prior written consent:

●

Guangzhou JIE may not transfer, encumber, grant a security interest in, or otherwise dispose of any equity interest in Yongzhou JIT, except as provided in the Exclusive Option Agreement;

●

Yongzhou JIT may not (i) sell, transfer, grant security interest in or otherwise dispose of any assets, business, revenue or interest, (ii) enter into any material contract except for those incurred in the ordinary course of business, or (iii) incur any liabilities (except for those incurred in the ordinary course of business) or extend loans or credit facilities to any third party;

●

Yongzhou JIT may not declare or pay any dividends and its shareholder must remit in full to Laidian any funds received from Yongzhou JIT except those funds payable to the holder of the 14.47% Unpledged Interest; and

●

Yongzhou JIT may not merge with or acquire any third parties, or make investment in any third parties.

Power of Attorney.

Under the Power of Attorney, Guangzhou JIE grants to Laidian the authority to exercise all of the powers given to Guangzhou JIE as a shareholder of Yongzhou JIT.

Yongzhou JIT was organized in 2018 in Yongzhou City in the Hunan Province of the PRC and is legally a wholly owned subsidiary of Guangzhou JIE. Yongzhou JIT is engaged in the business of developing medical technology and producing equipment based on its technology. Yongzhou JIT is best known for developing the first intelligence medicine vending machine.

In consideration of the agreements by the owners of Yongzhou JIT other than the holder of the 14.47% Unpledged Interest to the adoption of the Management Agreements, JRSIS issued to Jumi Group Company, Ltd. (“Jumi GCL”). 76,757,439 shares of its common stock. Jumi GCL is a holding company owned by Linhai Zhu, the director, chairman and the Chief Executive Officer of the Company, Yulin Investment (Guangzhou) Partnership L.P. (“Yulin IGP”), Jumi Intelligent Information Technology (Guangzhou)Partnership L.P. (“Jumi IIP”), who are the beneficial owners of 85.53% of Guangzhou JIE. The shares issued to Jumi GCL represent 92.9% of the outstanding shares of common stock of JRSIS.

For financial reporting purposes, the execution of the Management Agreements represents a “Reverse Acquisition” rather than a business combination and Yongzhou JIT is deemed to be the accounting acquirer in the transaction. The execution of the Management Agreements is being accounted for as a reverse acquisition and recapitalization. Yongzhou JIT is the acquirer for financial reporting purposes and JRSIS is the acquired company. Consequently, the assets and liabilities and the operations that will be reflected in the historical financial statements for periods prior to the execution of the Management Agreements will be those of Yongzhou JIT and will be recorded at the carrying amount basis of Yongzhou JIT, and the consolidated financial statements after execution of the Management Agreements will include the assets and liabilities of the Company and Yongzhou JIT, and the historical operations of Yongzhou JIT and operations of the Combined Company from the date of execution of the Management Agreements. No gain and loss recognized as a reverse acquisition and recapitalization.

JRSIS HEALTH CARE CORPORATION ITS SUBSIDIARIES

NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

Description of subsidiaries and VIEs

Name	Place of incorporation and kind of legal entity	Principal activities and place of operation	Effective interest held
JRSIS Health Care Corporation. (“JRSIS”)	State of Florida	Investment Holding	100%

JRSIS Health Care Limited. (“JRSIS-BVI”)	BVI	Investment Holding	100%

Runteng Medical Group Company Limited. (“Runteng” or “RT”)	Hong Kong, China	Investment Holding	100%

Laidian Technology (Zhongshan) Co., Ltd. (“Laidian”)	Zhongshan, China	Investment Holding	100%

Yongzhou Jumi Intelligent Technology Co., Ltd. (“Yongzhou JIT” or YZ JIT)	Yongzhou, China	Developing medical technology and producing equipment based on its technology	85.53% by Management Agreements

GOING CONCERN UNCERTAINTIES

The accompanying unaudited consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the discharge of liabilities in the normal course of business for the foreseeable future.

As reflected in the accompanying unaudited consolidated financial statements, for the three months ended March 31, 2024, the Company incurred a significant net loss of $169,948, the recurring operating loss resulted in an accumulated deficit of $3,588,254 as of March 31, 2024. The Company generated cash outflow form its operation of $204,937 and $16,507 for the three months ended March 31, 2024 and 2023, the continuing cash outflows resulted a working capital deficit of $581,125 as of March 31, 2024. Management believes these factors raise substantial doubt about the Company’s ability to continue as a going concern for the next twelve months.

The continuation of the Company as a going concern through the next twelve months is dependent upon (1) the continued financial support from its external financing, including bank loans and issuance of its shares to potential shareholders. Management believes that it can obtained additional bank loans and the issuance of common shares of the Company is available if the Company effort to do so, and (2) further implement management’s business plan to extend its operations and generate sufficient revenue and cash flows to meet its obligations. The Company’s operation is on the upward trend, and management believes that the Company’s operation can generate enough revenue and cash to meet its obligation in the normal course of business. While the Company believes in the viability of its strategy to increase sales volume and in its ability to raise additional funds, there can be neither any assurances to that effect, nor any assurance that the Company will be successful in securing sufficient funds to sustain the operations.

These conditions raise substantial doubt about the Company’s ability to continue as a going concern. These financial statements do not include any adjustments to reflect the possible future effect on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of these uncertainties. The Company is working to devote more efforts to improve its operation and generate more profits and cash flow. Management believes that the actions presently being taken to obtain additional funding and implement its strategic plan provide the opportunity for the Company to continue as a going concern.

JRSIS HEALTH CARE CORPORATION ITS SUBSIDIARIES

NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

●

Basis of Presentation and Consolidation

These accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”). These unaudited consolidated financial statements include the financial statements of the Company and its subsidiaries. All significant inter-company balances and transactions within the Company have been eliminated upon consolidation.

The unaudited interim condensed consolidated financial information as of March 31, 2024 and for the three months ended March 31, 2024 and 2023 have been prepared, pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information and footnote disclosures, which are normally included in annual consolidated financial statements prepared in accordance with US GAAP, have been omitted pursuant to those rules and regulations. The unaudited interim consolidated financial information should be read in conjunction with the consolidated financial statements and the notes thereto, included in the Company’s Form 10-K for the fiscal year ended December 31, 2023 previously filed with the SEC on May 26, 2024.

In the opinion of management, all adjustments (which include normal recurring adjustments) necessary to present a fair statements of the Company’s unaudited consolidated financial position as of March 31, 2024 and its unaudited consolidated results of operations for the three months ended March 31, 2024 and 2023, and its unaudited consolidated cash flows for the three months ended March 31, 2024 and 2023, as applicable, have been made. The interim results of operations are not necessarily indicative of the operating results for the fiscal year or any future periods.

●

Reclassification

Certain prior period balances were reclassified to conform to the current period presentation, mainly with consideration of reflecting the acquisition transaction by entering into and executing four agreements with Yongzhou Jumi Intelligent Technology Co., Ltd. (“Yongzhou JIT”) and Guangzhou Jumi Intelligent Equipment Co., Ltd. (“Guangzhou JIE”). None of these reclassifications had an impact on reported financial position or cash flows for any of the periods presented.

●

Use of Estimates

The preparation of the unaudited consolidated financial statements in conformity with US GAAP requires management to make estimates and judgments that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities on the date of the unaudited consolidated financial statements and the reported amounts of revenue and expenses during the reporting period.

The Company bases its estimates and judgments on historical experience and on various other assumptions and information that are believed to be reasonable under the circumstances. Estimates and assumptions of future events and their effects cannot be perceived with certainty and, accordingly, these estimates may change as new events occur, as more experience is acquired, as additional information is obtained and as our operating environment changes. Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary.

Significant estimates and assumptions made by management include, among others, useful lives and impairment of long-lived assets, collectability of accounts receivable, discount rate of leases and its impairment assessment, allowance for inventory, revenue recognition, product warranty liabilities, deferred tax and uncertain tax positions. While the Company believes that the estimates and assumptions used in the preparation of the consolidated financial statements are appropriate, actual results could differ from those estimates.

●

Fair Value Measurement

The Company follows the guidance of the Financial Accounting Standards Borad (“FASB”) Accounting Standard Codification (“ASC”) Topic 820, “Fair Value Measurements” (“ASC 820”), to address fair value measurement with respect to financial assets and liabilities. ASC 820 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and it considers assumptions that market participants would use when pricing the asset or liability.

JRSIS HEALTH CARE CORPORATION ITS SUBSIDIARIES

NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

ASC 820 also establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The three levels of inputs are:

Level 1:

Observable inputs that reflect unadjusted quoted prices for identical instruments traded in active markets;

Level 2:

Include other observable inputs are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, other observable inputs other than quoted price and market corroborated inputs; and

Level 3:

Unobservable inputs that are supported by little or no market activity.

ASC 820 describes three main approaches to measuring the fair value of assets and liabilities: (1) market approach; (2) income approach; and (3) cost approach. The market approach uses prices and other relevant information generated from market transactions involving identical or comparable assets or liabilities. The income approach uses valuation techniques to convert future amounts to a single present value amount. The measurement is based on the value indicated by current market expectations about those future amounts. The cost approach is based on the amount that would currently be required to replace an asset.

The Company’s financial instruments include cash, accounts receivable, advance to suppliers, prepaid expenses and other current assets, bank loans, accounts payable, amount due from/to related parties, and accrued expenses and other current liabilities. The carrying values of these financial instruments approximate their fair values due to their short-term maturities. The carrying amount of the long-term borrowing approximates its fair values since it bears an interest rate which approximates market interest rate.

●

Foreign Currencies Translation

The reporting currency of the Company is the United States Dollar (“US$”). The Company’s subsidiaries in the PRC maintain their books and records in their local currency, the Renminbi Yuan (“RMB”), which is the functional currency as being the primary currency of the economic environment in which these entities operate.

Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transaction. Monetary assets and liabilities denominated in currencies other than the functional currency are translated into the functional currency using the applicable exchange rates at the balance sheet dates. The resulting exchange differences are recorded in the statement of operations.

In general, for consolidation and reporting purposes, assets and liabilities of its subsidiaries whose functional currency is not the US$ are translated into US$, in accordance with ASC Topic 830-30, “Translation of Financial Statement”, using the exchange rate on the balance sheet date, equity accounts are translated at its historical rates; revenue and expenses are translated at average rates prevailing during the period. The gains and losses resulting from translation of financial statements of foreign subsidiaries are recorded as a separate component of accumulated other comprehensive income within the statement of stockholders’ equity.

Translation of amounts from RMB into US$ has been made at the following exchange rates for the respective periods:

	March 31, 2024		March 31, 2023
Period-end RMB:US$1 exchange rate		7.2203		6.8676
For the three months ended average RMB:US$1 exchange rate		7.1885		6.8423

JRSIS HEALTH CARE CORPORATION ITS SUBSIDIARIES

NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

●

Related Parties

The Company adopted ASC 850, Related Party Disclosures, for the identification of related parties and disclosure of related party transactions. Related parties include: (a) Affiliates of the entity, who directly or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with an entity; (b) Entities for which investments in their equity securities would be required to be accounted for by the equity method by the investing entity; (c) Trusts for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of management; (d) Principal owners, who record or known beneficial owners of more than 10 percent of the voting interests, of the entity and members of their immediate families; (e) Management of the entity and members of their immediate families; (f) Other parties with which the entity may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; (g) Other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests. The Company disclosed all material related party transactions.

●

Segment Reporting

ASC Topic 280, “Segment Reporting” establishes standards for reporting information about operating segments on a basis consistent with the Company’s internal organization structure as well as information about geographical areas, business segments and major customers in financial statements. The Company’s chief operating decision maker has been identified as the CEO who reviews consolidated results of the Company when making decisions about allocating resources and assessing performance. The Company is domiciled in the United States while its mainly business operation is within the PRC and earns majority of the revenue from external customers attributed from the PRC. As a whole and hence, the Company has only one operating segment for the periods ended March 31, 2024 and 2023, respectively.

●

Cash

Cash consists of cash on hand and deposits in financial institutions which is readily available in checking and saving accounts. The Company maintains cash with various financial institutions in the PRC and are uninsured. The Company has not experienced any losses in bank account and believes it is not exposed to any risk on its cash held in bank accounts.

●

Accounts Receivable

Accounts receivable is arisen from revenue from contracts with customers and reported at its original amount less an allowance for expected credit losses. Accounts receivables original amount recorded at the invoiced amount with no interest bearing, due various in contractual payment terms, generally 30 to 90 days from delivery. Credit is granted based on management’s evaluation of a customer's financial condition, the customer credit-worthiness and their payment history. Accounts receivable outstanding longer than the contractual payment terms are considered past due. Past due balances over 90 days and over a specified amount are reviewed individually for collectability. At the end of each period, the Company specifically evaluates individual customer’s financial condition, credit history, and the current economic conditions to monitor the progress of the collection of accounts receivables. The Company will consider the allowance for any estimated credit losses resulting from the inability of its customers to make required payments. Account balances are charged off against the allowance for credit losses after all means of collection have been exhausted and the potential for recovery is considered remote.

●

Advances To Suppliers

Advances to suppliers consist of prepayments to our vendors, such as outsource service, marketing promotion parties. We typically receive products from vendors within three to nine months after making prepayments. We continuously monitor delivery from, and payments to, our vendors while maintaining a provision for estimated credit losses based upon historical experience and any specific supplier issues, such as discontinuing of inventory supply, that have been identified. If we have difficulty receiving products from a vendor, we take the following steps: cease purchasing products from such vendor, ask for return of our prepayment promptly, and if necessary, take legal action. If all of these steps are unsuccessful, management then determines whether the prepayments should be reserved or written off. As of March 31, 2024 and December 31, 2023, the balance of allowance for doubtful accounts was $0 and $0, respectively.

JRSIS HEALTH CARE CORPORATION ITS SUBSIDIARIES

NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

●

Inventories

Inventories consist of raw material and parts, work-in-progressing, and finished goods of the Company’s product, such as medicine or goods vending machine, health micro-consulting room. Inventories are stated at the lower of cost and net realizable value. Cost is determined using weighted average method. Net realizable value equal to the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The Company carries out physical inventory counts from time to time and at least once within a fiscal year. The Company reviews historical sales activity quarterly to determine excessive, slow-moving items, and items that damage, physical deterioration, obsolescence to determine if evidence exists that the net realizable value of inventory is lower than its cost, if any, the difference shall be recognized as a loss in earnings in the period in which it occurs.

●

Equipment and Vehicles

Equipment and vehicles are stated at cost less accumulated depreciation and impairment, if any. Depreciation is calculated on the straight-line basis over the following expected useful lives from the date on which they become fully operational and after taking into account their estimated residual values:

Items	Expected useful lives	Residual value
Production line and equipment	3-10 years		0	%
Office equipment	2-5 years		0	%
Vehicle	3-5 years		0	%

Expenditures for repairs and maintenance are expensed as incurred. When assets have been retired or sold, the cost and related accumulated depreciation are removed from the accounts and any resulting gain or loss is recognized in the results of operations.

●

Intangible Assets

Intangible assets consist primarily of patents of patent of utility model and copyright of software. Intangible assets are stated at cost less accumulated amortization and impairment, if any. Intangible assets are amortized using the straight-line method with the following estimated useful lives:

		Expected useful lives
Utility model		10 years
Copyright		10 years

●

Impairment of Long-lived Assets

In accordance with the provisions of ASC Topic 360, “Impairment or Disposal of Long-Lived Assets”, all long-lived assets such as property, plant and equipment held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is evaluated by a comparison of the carrying amount of an asset to its estimated future undiscounted cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amounts of the assets exceed the fair value of the assets.

●

Leases

The Company stated lease transactions in accordance with the FASB ASC Topic 842 Leases.

Identify a lease

At inception of a contract, the Company assesses whether a contract is, or contains, a lease. A contract is or contains a lease if it conveys the right to control the use of an identified asset for a period of time in exchange of a consideration. To assess whether a contract is or contains a lease, the Company assess whether the contract involves the use of an identified asset, whether it has the right to obtain substantially all the economic benefits from the use of the asset and whether it has the right to control the use of the asset.

JRSIS HEALTH CARE CORPORATION ITS SUBSIDIARIES

NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

Lease classification

Lease classification for leases under which the Company is a lessor is evaluated at lease commencement and leases not classified as sales-type leases or direct financing leases are classified as operating leases. Leases qualify as sales-type leases if the contract includes either transfer of ownership clauses, certain purchase options, a lease term representing a major part of the economic life of the asset, or the present value of the lease payments and residual guarantees provided by the lessee exceeds substantially all of the fair value of the asset. Additionally, leasing an asset so specialized that it is not deemed to have any value to the Company at the end of the lease term may also result in classification as a sales-type lease. Leases qualify as direct financing leases when the present value of the lease payments and residual value guarantees provided by the lessee and unrelated third parties exceeds substantially all of the fair value of the asset and collection of the payments is probable. There are not leases under which the Company is a lessor during the periods of the accompanying financial statements.

Lease classification for leases under which the Company is a lessee is evaluated at lease commencement as finance or operating leases. Leases qualify as finance leases if the lease transfers ownership of the asset at the end of the lease term, the lease grants an option to purchase the asset that the Company is reasonably certain to exercise, the lease term is for a major part of the remaining economic life of the asset, or the present value of the lease payments exceeds substantially all of the fair value of the asset. Leases that do not qualify as finance leases are deemed to be operating leases.

In accordance with the FASB ASC Topic 842, the Company recognizes a right-of-use asset and a lease liability at the commencement date of the of the lease and recognizes in profit or loss the lease cost or expense during the lease term. As an accounting policy, the Company elect not to recognize a right-of-use asset and a lease liability to a short-term lease which with a term of 12 months or less, instead, recognizes the lease payments in profit or loss on a straight-line basis over the lease term. Variable lease payments recorded in earnings in the period in which the obligation for those payments is incurred. The Company generally uses an incremental borrowing rate as discount rate to measure its lease liabilities, as the rate implicit in the lease is typically not readily determinable. Certain lease agreements include renewal options that are under the Company’s control. The Company includes optional renewal periods in the lease term only when it is reasonably certain that the Company will exercise its option.

Right-of-use assets

The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and less any lease incentive received.

Lease liabilities

Lease liability is initially measured at the present value of the outstanding lease payments at the commencement date, discounted using the Company’s incremental borrowing rate. Lease payments included in the measurement of the lease liability comprise fixed lease payments, variable lease payments that depend on an index or a rate, amounts expected to be payable under a residual value guarantee and any exercise price under a purchase option that the Company is reasonably certain to exercise. Lease liability is measured at amortized cost using the effective interest rate method. It is re-measured when there is a change in future lease payments, if there is a change in the estimate of the amount expected to be payable under a residual value guarantee, or if there is any change in the Company assessment of option purchases, contract extensions or termination options.

●

Revenue Recognition

The Company adopted ASC Topic 606, Revenue from Contract with Customers (“ASC 606”) for all periods presented. Under ASC 606, revenue is recognized when control of the promised goods and services is transferred to the Company’s customers and the performance obligation was satisfied, in an amount that reflects the consideration that the Company expects to be entitled to in exchange for those goods and services transferred. The Company determines revenue recognition through the following steps:

	●	Identify the contract with a customer;

	●	Identify the performance obligations in the contract;

JRSIS HEALTH CARE CORPORATION ITS SUBSIDIARIES

NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

	●	Determine the transaction price;

	●	Allocate the transaction price to the performance obligations in the contract; and

	●	Recognize revenue when (or as) the entity satisfies a performance obligation.

The transaction price is allocated to each performance obligation on a relative standalone selling price basis. The transaction price allocated to each performance obligation is recognized as revenue when that performance obligation is satisfied by the control of the promised goods and services is transferred to the customers, which at a point in time or over time as appropriate.

The Company’s revenue consists primary of sales of machine, design and development software systems for customers base on the Company’s intelligent and communication technology, system installation and maintenances services.

The Company determined for each performance obligation identified at contract inception whether it satisfies the performance obligation over time or satisfies the performance obligation at a point in time. If an entity does not satisfy a performance obligation over time, the performance obligation is satisfied at a point in time.

The Company recognizes revenue from sales of machine at the point in time when the Company has transferred physical possession of the goods to the customer and the customer has accepted the goods, therefore, indicating as control of the goods has been transferred to the customer.

The Company determined each performance obligation identified from contract with customer of design and development software systems and contracts from system installment and maintenance at the inception of each contract whether it satisfied over time of at point in time. During the three months ended March 31, 2024 and 2023, all the performance obligation identified from the contracts are satisfied at point in time and its related revenue are recognized at point in time.

●

Contract Balances

When a contract with customers has performed, the Company presents the contract in the consolidated balance sheet as a contract asset or a contract liability, depending on the relationship between the Company’s performance and the customer’s payment.

Contract assets or accounts receivable

A contract asset is the Company’s right to consideration in exchange for goods or services that the Company has transferred to a customer. A receivable is recorded when the Company has an unconditional right to consideration. A right to consideration is unconditional if only the passage of time is required before payment of that consideration is due. The Company does not have material contract assets.

Contract liabilities

The contract liability represents the billings or cash received for goods or services in advance of revenue recognition which is recognized as revenue when all of the Company’s revenue recognition criteria are met. The Company presents contract liabilities in its financial statements as advances from customers.

●

Cost of Revenue

Cost of revenue consists primarily of material costs, direct labor, depreciation, and manufacturing overhead, which are directly attributable to the manufacture of products and other costs directly related to rendering of services or projects performance.

●

Advertising Expenses

The Company expenses advertising costs as incurred and includes it in selling expenses. The Company recorded $97,754 and $0 of advertising and promotional expenses for the three months ended March 31, 2024 and 2023, respectively.

JRSIS HEALTH CARE CORPORATION ITS SUBSIDIARIES

NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

●

Research and Development Expenses

Research and development expenses consist primarily of salary and welfare for research and development department personnel and materials used for research. The Company reported $10,254 and $30,295 as research and development expenses for the three months ended March 31, 2024 and 2023, respectively.

●

Comprehensive Income

ASC Topic 220, “Comprehensive Income”, establishes standards for reporting and display of comprehensive income, its components and accumulated balances. Comprehensive income as defined includes all changes in equity during a period from non-owner sources. Accumulated other comprehensive income, as presented in the accompanying consolidated statement of stockholders’ equity, consists of changes in unrealized gains and losses on foreign currency translation. This comprehensive income is not included in the computation of income tax expense or benefit.

●

Income Taxes

Income taxes are determined in accordance with the provisions of ASC Topic 740, “Income Taxes” (“ASC 740”). Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted income tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Any effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

ASC 740 prescribes a comprehensive model for how companies should recognize, measure, present, and disclose in their financial statements uncertain tax positions taken or expected to be taken on a tax return. Under ASC 740, tax positions must initially be recognized in the financial statements when it is more likely than not the position will be sustained upon examination by the tax authorities. Such tax positions must initially and subsequently be measured as the largest amount of tax benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority assuming full knowledge of the position and relevant facts.

For the three months ended March 31, 2024 and 2023, the Company did not have any interest and penalties associated with tax positions. As of March 31, 2024, the Company did not have any significant unrecognized uncertain tax positions.

The Company conducts the majority of its businesses in the PRC and is subject to tax in this jurisdiction. As a result of its business activities, the Company files tax returns that are subject to examination by a foreign tax authority.

●

Value Added Tax

Sales revenue represents the invoiced value of goods, net of Value-Added Tax (“VAT”). All of the Company’s goods or services are sold in the PRC and are subject to a VAT on the gross sales price. The VAT rates range from 6% to 13%, depending on the type of goods or services sold. The VAT may be offset by qualified VAT paid by the Company on raw materials and other materials included in the cost of producing or acquiring its finished products. The Company’s subsidiaries in PRC were required to file VAT tax return each month. The Company recorded a VAT payable net of payments if VAT payable on the gross sales is larger than VAT paid by the Company on purchase of materials or finished goods, on the contrary, the Company recorded VAT deductible, VAT deductible can be used to deducted VAT payable in the future.

●

Income (Loss) Per Share

The Company calculates income (loss) per share in accordance with ASC Topic 260, “Earnings per Share.” Basic income (loss) per share is computed by dividing the net income (loss) attributable to the holders of common shares by the weighted-average number of common shares outstanding during the period. Diluted income (loss) per share is computed similar to basic income (loss) per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common stock equivalents had been issued and if the additional common shares were dilutive.

JRSIS HEALTH CARE CORPORATION ITS SUBSIDIARIES

NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

●

Recent Accounting Pronouncements

In November 2023, the Financial Accounting Standards Board (“FASB”) issued a new standard to improve reportable segment disclosures. The guidance expands the disclosures required for reportable segments in our annual and interim consolidated financial statements, primarily through enhanced disclosures about significant segment expenses. The standard will be effective for us beginning with our annual reporting for fiscal year 2025 and interim periods thereafter, with early adoption permitted. We are currently evaluating the impact of this standard on our segment disclosures.

In December 2023, the FASB issued a new standard to improve income tax disclosures. The guidance requires disclosure of disaggregated income taxes paid, prescribes standardized categories for the components of the effective tax rate reconciliation, and modifies other income tax-related disclosures. The standard will be effective for us beginning with our annual reporting for fiscal year 2026, with early adoption permitted. We are currently evaluating the impact of this standard on our income tax disclosures.

The Company does not believe other recently issued but not yet effective accounting standards, if currently adopted, would have a material effect on the consolidated balance sheets, consolidated statements of income and consolidated statements of cashflows.

VARIABLE INTEREST ENTITY AND OTHER CONSOLIDATION MATTERS

On November 30, 2023, the Company and Yongzhou JIT closed a reverse acquisition and then, Laidian, an indirectly wholly-owned subsidiary of JRSIS, entered into four agreements with Yongzhou JIT and Guangzhou JIE (the “Management Agreements”). The key terms of these Management Agreements are summarized in Note 1 - Organization and Business Background of previous notes to these financial statements.

In accordance with FASB ASC 810, Variable Interest Entity (“VIE”) is an entity that has either a total equity investment that is insufficient to permit the entity to finance its activities without additional subordinated financial support, or whose equity investors lack the characteristics of a controlling financial interest, such as through voting rights, right to receive the expected residual returns of the entity or obligation to absorb the expected losses of the entity. The variable interest holder, if any, that has a controlling financial interest in a VIE is deemed to be the primary beneficiary and must consolidate the VIE. Laidian is deemed to have a controlling financial interest and be the primary beneficiary of Yongzhou JIT under the term of Management Agreements, because it has both of the following characteristics:

power to direct activities of Yongzhou JIT that most significantly impact its economic performance, and

obligation to absorb losses of the entity that could potentially be significant to Yongzhou JIT or right to receive benefits from the entity that could potentially be significant to Yongzhou JIT.

In addition, as all of these Management Agreements are governed by PRC law and provide for the resolution of disputes through arbitration in the PRC, they would be interpreted in accordance with PRC law and any disputes would be resolved in accordance with PRC legal procedures. The legal environment in the PRC is not as developed as in other jurisdictions, such as the United States. As a result, uncertainties in the PRC legal system could further limit the Company’s ability to enforce these Management Agreements. Furthermore, these contracts may not be enforceable in China if PRC government authorities or courts take a view that such contracts contravene PRC laws and regulations or are otherwise not enforceable for public policy reasons. In the event the Company is unable to enforce these Management Agreements, it may not be able to exert effective control over Yongzhou JIT and its ability to conduct its business may be materially and adversely affected.

All of the Company’s main current operations are conducted through Yongzhou JIT. Current regulations in China permit Yongzhou JIT to pay dividends to the Company only out of its accumulated distributable profits, if any, determined in accordance with their articles of association and PRC accounting standards and regulations. The ability of Yongzhou JIT to make dividends and other payments to the Company may be restricted by factors including changes in applicable foreign exchange and other laws and regulations.

In the opinion of management, (i) the corporate structure of the Company is in compliance with existing PRC laws and regulations; (ii) the Management Agreements are valid and binding, and do not result in any violation of PRC laws or regulations currently in effect; and (iii) the business operations of Laidian and the VIE are in compliance with existing PRC laws and regulations in all material respects.

JRSIS HEALTH CARE CORPORATION ITS SUBSIDIARIES

NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

However, there are substantial uncertainties regarding the interpretation and application of current and future PRC laws and regulations. Accordingly, the Company cannot be assured that PRC regulatory authorities will not ultimately take a contrary view to the foregoing opinion of its management. If the current corporate structure of the Company or the Management Agreements is found to be in violation of any existing or future PRC laws and regulations, the Company may be required to restructure its corporate structure and operations in the PRC to comply with changing and new PRC laws and regulations. In the opinion of management, the likelihood of loss in respect of the Company’s current corporate structure or the Management Agreements is remote based on current facts and circumstances.

The carrying amount of the major classes of assets and liabilities of the VIE in the PRC are included in the consolidated financial statements as of March 31, 2024 and December 31, 2023 consist of the following:

	March 31, 2024		December 31, 2023
Current assets:
Cash	$	323,610	$	108,958
Accounts receivable, net		603,022		714,658
Accounts receivable, net - related parties		100,376		121,086
Advances to suppliers		251,404		345,961
Amount due from related parties		2,631		1,620
Inventories		445,500		455,240
Prepayments and other receivables		89,278		77,211
Total current assets		1,815,821		1,824,734

Non-current assets:
Equipment and vehicle, net		46,193		50,025
Intangible assets, net		243,897		257,334
Right of use assets		2,161		3,277
Total assets from VIE		2,108,072		2,135,370

Current liabilities:
Short-term loans		1,368,261		983,007
Long-term loans due within one year		24,534		18,713
Accounts payable, trade		496,793		540,086
Accounts payable, trade - related parties		66,922		261,200
Advances from customers		223,121		218,313
Amount due to related parties		25,565		5,761
Taxes payable		39,552		18,845
Other payables and accrued liabilities		169,938		221,869
Operating lease liabilities, current		2,161		3,277
Total current liabilities		2,416,847		2,271,071
Non-current liabilities
Long-term loans - noncurrent portion		18,401		24,950
Operating lease liabilities, non-current		-		-
Total liabilities		2,435,248		2,296,021

JRSIS HEALTH CARE CORPORATION ITS SUBSIDIARIES

NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

The summarized operating results of the VIE in the PRC included in the Company’s consolidated financial statements for the periods indicated consist of the following:

	For the Three Months ended March 31,
	2024			2023
Revenue	$	500,420		$	476,994
Cost of revenue		443,198			325,602
Gross profit		57,222			151,392

Operating expenses		218,128			73,868
Other income (expenses)		(9,043	)		(16,106	)
Income (loss) before income taxes		(169,949	)		61,418

Income taxes		-			8,283
Net loss from operations	$	(169,949	)	$	53,135

As of March 31, 2024, the VIE had amount due to non-VIE entities of the Company of approximated $20,045, representing the amount YZ JIT received the amount of the consideration of common shares JRSIS issued during the three months as of March 31, 2024. As of December 31, 2023 the VIE had not incurred any amount due to non-VIE subsidiaries of the Company.

All material related party transactions are disclosed in Note 12 or elsewhere in these consolidated financial statements. For the three months ended March 31, 2024, JRSIS issued 2,004,545 common shares to certain personal in the PRC, the consideration of these shares issued were amount to $20,045.45 (approximately RMB 143,686) was received by Yongzhou JIT, the VIE of the Company, which resulted the ending balance of amount due to JRSIS as of March 31, 2024. For the three months ended March 31, 2023 the VIE have not entered into any transaction with other subsidiaries that are not VIEs. All transactions incurred and ending balances between VIE and Non-VIEs would be eliminated upon consolidation.

Under the Management Agreements, the Company has the power to direct activities of the VIE and can have assets transferred out of the VIE under its control. Therefore, the Company considers that there is no asset in any of the VIE that can be used only to settle obligations of the VIE, except for registered capital and PRC statutory reserves. As the VIE is incorporated as limited liability companies under the Company Law of the PRC, creditors of the VIE do not have recourse to the general credit of the Company for any of the liabilities of the VIE.

The Company and its directly and indirectly wholly owned subsidiaries, JRSIS-BVI, Runteng and Laidian do not have any substantial assets or liabilities or result of operations. They were incorporated for the purpose of providing a corporation structure for the Yongzhou JIT to be listed in the market and to raise additional capital for its development.

ACCOUNTS RECEIVABLE

The accounts receivable, excluded accounts receivable from related parties, consisted of the following:

	March 31, 2024		December 31, 2023
Accounts receivable, cost	$	603,022	$	714,658
Less: allowance for credit loss		-		-
Accounts receivable, net	$	603,022	$	714,658

The Company did not record any allowance for credit loss of accounts receivable for the three months ended March 31, 2024 and 2023.

INVENTORIES

Inventories consisted of the following:

	March 31, 2024			December 31, 2023
Raw materials and parts	$	303,197		$	302,322
Working-in-progressing		69,773			128,900
Finished goods		257,326			212,364
Subtotal		630,296			643,586
Less: impairment allowance		(184,796	)		(188,346	)
Inventories, net of allowance for impairment	$	445,500		$	455,240

JRSIS HEALTH CARE CORPORATION ITS SUBSIDIARIES

NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

The Company did not record any allowance for impairment of inventories for the three months ended March 31, 2024 and 2023, respectively. During the three months ended March 31, 2024 and 2023, there were $412 and $6,202 of allowance for impairment of inventories transferred out due to disposal of part of impaired inventories.

PREPAYMENTS AND OTHER RECEIVABLES

Prepayments and other receivables present the amount the Company prepay for deposit payment for leases and utilities, security deposits of certain contracts, advances to employees for ordinary business purpose for the company which might reimburse or return from the employee, VAT deductible and advances for employee’s social security payments such as and so on. The table below set forth the balance of a brief categories as of March 31, 2024 and December 31, 2023.

	March 31, 2024		December 31, 2023
Deposits	$	20,632	$	20,981
Advances to personnel		1,385		1,408
VAT deductible		64,054		51,714
Other receivables		3,207		3,108
		89,278		77,211
Less: allowance for doubtful accounts		-		-
Prepayments and other receivables, net	$	89,278	$	77,211

Management evaluated the recoverable value of these balances periodically accordingly to the Company’s credit policy and allowance for credit loss, if any. For the three months ended March 31, 2024 and 2023, the Company did not report any allowance of the credit loss of prepayment and other receivables.

EQUIPMENT AND VEHICLES

Equipment and vehicles consisted of the following:

	March 31, 2024			December 31, 2023
Production line and equipment	$	106,314		$	108,116
Office equipment and furniture		32,210			32,757
Transportation instrument		6,591			6,703
		145,115			147,576
Less: accumulated depreciation		(98,922	)		(97,552	)
Equipment and vehicles, net	$	46,193		$	50,024

The Company recorded depreciation expense on the equipment and vehicle for the three months ended March 31, 2024 and 2023 were $3,010 and $4,752, respectively. No impairment loss recognized during the three months ended March 31, 2024 and 2023.

INTANGIBLE ASSETS

Intangible assets consist of the following:

	March 31, 2024			December 31, 2023
Utility model	$	41,027		$	41,722
Copyright		324,818			330,327
		365,845			372,049
Less: accumulated amortization		(121,948	)		(114,715	)
Land use right, net	$	243,897		$	257,334

The Company recorded amortization expense on these intangible assets for the three months ended March 31, 2024 and 2023 were $9,187 and $9,651, respectively.

JRSIS HEALTH CARE CORPORATION ITS SUBSIDIARIES

NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

The estimated amortization expense on these intangible assets in the next five years and thereafter is as follows:

Year ending March 31:
2025	$	36,584
2026		36,584
2027		36,584
2028		36,584
2029		36,584
Thereafter		60,977
Total:	$	243,897

10.

LEASES

The following consisted of leases under which the Company is a lessee.

Operating Lease

In October 2022, the Company entered in a lease contract to lease five dormitories room for the use as dormitory of staffs (“2022 Dormitory Lease”). According to the lease contract, the lease term is about 24 months which during from October 2022 to September 2024; at the end of the contract, the Company should inform the lessor 30 days in advance to the end of the contract if the Company would like to continue to lease the dormitory room and the leased space and price will be re-negotiated and agreed by the two parties in the circumstance at that time; the lease payments are $369 (appropriate RMB 2,615) per month and payable quarterly in advance. At the inception of the lease contract, the Company could not determine that it will renew the lease contract in the same terms.

Short-term Lease

On May 2022 and May 2023, respectively, the Company enter into lease contracts to rent a plant area for use of its product manufacturing, laboratory for research and development and production office (“Plant Leases”). Plant leases were renewed every year upon re-negotiation the lease term with the lessor. Each Plant Lease with a lease term of 12 months vary of the plant sizes and unit rental fee, each Plant Lease should be treated as a separately lease agreement. The Company elected not to recognize a right-of-use asset and lease liability requirement to these Plants Leases, because it has a lease term of 12 months or less. The Company recognized the lease payments in profit or loss on a straight-line basis over the lease term and variable lease payments in the period in which the obligation for those payments is incurred.

As of March 31, 2024 and December 31, 2023, the Company reported the following amounts in the Company’s balance sheets:

	March 31, 2024		December 31, 2023
Assets
Right-of-use assets	$	2,161	$	3,277
Total	$	2,161	$	3,277

Liabilities
Finance lease liabilities-current	$	-	$	-
Operating lease liabilities-current		2,161		3,277
Finance lease liabilities-non-current		-		-
Operating lease liabilities-non-current		-		-
Total of leases liabilities	$	2,161	$	3,277

JRSIS HEALTH CARE CORPORATION ITS SUBSIDIARIES

NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

The following table illustrated quantitative information for the Company as a lessee for the periods indicated:

	For the Three Months Ended March 31,
	2024			2023
Lease Cost:
Finance lease cost	$			$
Amortization of right-of-use assets		-			-
Interest on lease liabilities		-			-
Operating lease cost		1,091			1,147
Short-term lease cost		19,332			20,310
Variable lease cost		-			-
Sublease income		-			-
Total lease cost	$	20,423		$	21,457

Other information
(Gain) and losses on sale and lease back transactions, net	$			$	-
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows from finance leases	$			$	-
Operating cash flows from operating leases	$	(1,091	)	$	(2,293	)
Financing cash flow from finance leases	$	-		$	-
Right-of-use assets obtained in exchange for new finance lease liabilities	$	-		$	-
Right-of-use assets obtained in exchange for new operating lease liabilities	$	-		$	-
Weighted-average remaining lease term – finance leases		-			-
Weighted-average remaining lease term – operating leases		0.42			0.75
Weighted-average discount rate – finance leases		-			-
Weighted-average discount rate – operating leases		4.75	%		4.75	%

The following table is a maturity analysis of it operating lease liabilities that showing the minimum annual undiscounted cash flows the Company will be paid made in the following five years and total of thereafter as of March 31, 2024:

2025	$	2,173
2026		-
2027		-
2028		-
2029		-
Thereafter		-
Total of undiscounted cash flows		2,173
Less interest accrued		12
Operating lease liabilities	$	2,161

11.

REVENUE

The Company’s revenue can be briefly classified into two sources, including 1) sales of terminal products, such as medicine vending machine, that the Company self-manufactured and assembled in its plant, and 2) services rendered, such as installment and maintenance terminal system, designing and development of application system to its customers. Goods and services that the Company transferred deriving its revenue are all based on the Company’s technology and manufacturing capacity.

The Company derived its revenue from both third-party customers and related party customer. Guangzhou JIE, the legal parent of Yongzhou JIT in the PRC and both under the common control of Linhai Zhu, the CEO of the Company, generally purchases certain machine from Yongzhou JIT and resales to its customers, and also had Yongzhou JIT to provided instalment and maintenance service for its customers from time to time and pays case by case under a negotiated range of charge rate to Yongzhou JIT. Ending customers of the Company’s goods and services mainly includes medicine service organization, business entities and local government.

JRSIS HEALTH CARE CORPORATION ITS SUBSIDIARIES

NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

During the three months ended March 31, 2024 and 2023, all customers of the Company are within the PRC and all revenue derived within the PRC.

The following table set forth quantitative information related to revenue for the periods indicated:

	For the Three Months Ended March 31,
	2024		2023
Revenue:
Goods sold directly to third parties	$	401	$	18,122
Goods sold to related parties		158,423		156,572
Total revenue from goods sold		158,824		174,694
Service rendered directly to third parties		229,927		-
Service rendered to related parties		111,669		302,300
Total revenue from service rendered		341,596		302,300
Total revenue	$	500,420	$	476,994

Cost of revenue:
Goods sold directly to third parties	$	255	$	4,224
Goods sold to related parties		121,956		68,571
Total cost of revenue from goods sold		122,211		72,794
Service rendered directly to third parties		212,568		-
Service rendered to related parties		108,418		252,808
Total cost of revenue from service rendered		320,987		252,808
Total cost of revenue	$	443,198	$	325,602

Gross profit	$	57,222	$	151,392

12.

RELATED PARTIES AND RELATED PARTIES TRANSACTIONS

Related parties:

The following related parties involved in transactions with the Company during the three months ended March 31, 2024 and 2023, or had ending balance as of March 31, 2024 and December 31, 2023, respectively.

Name of related parties		Relationship
Guangzhou Jumi Intelligent Equipment Co., Ltd. (“Guangzhou JIE”)		The legal parent of Yongzhou JIT in the PRC and under common control of Linhai Zhu.
Kangmi Yaolian (Guangzhou) Wulinwang Co., Ltd.		Guangzhou JIE held 15% equity interest of this company and Linhai Zhu also the CEO of this company.
Shanghai Jiuchenbengou Information and Technology Co., Ltd.		Guangzhou JIE held 18% equity interest of this entity and Guangzhou JIE had significant influence on this company’s operation and financing activities.
Yongzhou Jingmi Health Technology Co., Ltd.		Guangzhou JIE directly and indirectly held 51% equity interest of this entity and under the control of Guangzhou JIE and Mr. Linhai Zhu
Linhai Zhu, his spouse Mei Liu		Linhai Zhu is the CEO of the Company and a majority shareholder of the Company.
Zhuowei Zhong		One of the Company’s directors and the CEO of the Company until November 30, 2023.
Lugeng Zhou		The General Manager of Yongzhou JIT

JRSIS HEALTH CARE CORPORATION ITS SUBSIDIARIES

NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

Accounts receivable, net – related parties

Accounts receivable, net – related parties consisted of the following:

Name of related parties:	March 31, 2024			December 31, 2023
Guangzhou Jumi Intelligent Equipment Co., Ltd. (1)	$	(2,071	)	$	-
Kangmi Yaolian (Guangzhou) Wulinwang Co., Ltd. (2)		61,244			65,100
Shanghai Jiuchenbengou Information and Technology Co., Ltd. (2)		41,203			41,902
Yongzhou Jingmi Health Technology Co., Ltd. (2)		-			14,084
	$	100,376		$	121,086

(1)

the amount presents the balance of (advance from) accounts receivable from goods sold to Guangzhou Jumi Intelligent Equipment Co., Ltd.

(2)

Amounts derived from the accounts receivable of goods sold to such parties for current and prior periods.

Amount due from related parts

Name of related parties:	March 31, 2024		December 31, 2023
Lugeng Zhou (1)	$	-	$	494
Yongzhou Jingmi Health Technology Co., Ltd. (2)		2,631		1,126
	$	2,631	$	1,620

(1)

The balance was the interest due from Mr. Lugeng Zhou, Yongzhou JIT’s general manager.

(2)

The ending balance YZ JIT loaned to related parties free of interest and due on demand.

Accounts payable – related parties:

Name of related parties:	March 31, 2024		December 31, 2023
Guangzhou Jumi Intelligent Equipment Co., Ltd. (1)		66,922		261,200
	$	66,922	$	261,200

(1)

the amount presents the balance of accounts payable to intangible assets purchased from Guanzhou Jumi Intelligent Equipment Co., Ltd.

Amount due to related parties

Name of related parties:	March 31, 2024		December 31, 2023
Linhai Zhu	$	5,665	$	5,760
Zhuowei Zhong		-		9,157
	$	5,665	$	14,917

JRSIS HEALTH CARE CORPORATION ITS SUBSIDIARIES

NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

Related parties’ transactions

Revenue recognized from goods and service transferred to related parties amount to $270,092 and $458,872, or 54% and 96% of total revenue, for the three months ended March 31, 2024 and 2023, respectively.

Purchase of raw materials and software to be used in assembling of machine from related parties amount to $163,088 and 282,063, or 38% and 70% of total purchase, for the three months ended March 31, 2024 and 2023, respectively.

No capital contributed from Guangzhou JIE for the three months ended March 31, 2024 and 2023, respectively.

Guarantee provided by related parties consisted of the following:

On May 20, 2022, Linhai Zhu, his spouse Mei Liu and Guangzhou Jumi Intelligent Equipment Co., Ltd. provided guarantee for the short-term loan from Bank of China with outstanding balance approximately of $507,452 as of March 31, 2023.

On July 20, 2022, Linhai Zhu, his spouse Mei Liu and Guangzhou Jumi Intelligent Equipment Co., Ltd. provided guarantee for the short-term loan from Postal Savings Bank of China with outstanding balance approximately of $336,513 as of March 31, 2023.

On August 16, 2022, Linhai Zhu and his spouse Mei Liu provided guarantee for the short-term loan from China Construction Bank with outstanding balance approximately of $551,120 as of March 31, 2024.

On June 29, 2023, Linhai Zhu, his spouse Mei Liu and Guangzhou Jumi Intelligent Equipment Co., Ltd. provided guarantee for the short-term loan from Bank of China with outstanding balance of $415,495 as of March 31, 2024.

13.

BANK LOANS

Short-term Loans

Short-term loans consist of the following:

	March 31, 2024		December 31, 2023
In June 2023, YZ JIT borrowed from Bank of China amount to US$422,541 (approximated RMB 3,000,000) with a fixed annual interest rate at 3.80%, due on June 29, 2024. This loan was secured by Mr. Linhai Zhu, the CEO of the Company, and his spouse Ms. Liu Mei and Guangzhou JIE., a related company under common control of Linhai Zhu.		415,495		422,541

In August 2022, YZ JIT borrowed from China Construction Bank amount to US$579,945 (approximated RMB 4,000,000) with a fixed annual interest rate at 4.50%, originally maturity on August 16, 2023. YZ JIT repaid RMB 20,746.58 during 2023 and extended the remaining loan principal amount to US$560,466 (approximated RMB3,979,253.42) till August 16, 2024 with the annual interest rate of 4.75%. This loan was secured by Mr. Linhai Zhu, the CEO Company, and his spouse Ms. Liu Mei and Guangzhou JIE, a related company under common control of Linhai Zhu.		551,120		560,466

On March 5, 2024, YZ JIT borrowed from Industrial and Commercial Bank of China (ICBC) amount to $401,645 (Approximated RMB2,900,000) with fixed annual interest rate at 3.65%, maturity date of March 5, 2025. No guarantee and no collateral provided for this loan.		401,646		-

Total	$	1,368,261	$	983,007

JRSIS HEALTH CARE CORPORATION ITS SUBSIDIARIES

NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

Long-term loans

Long-term loans consist of following:

	March 31, 2024			December 31, 2023
In December 2023, YZ JIT and Shenzhen Qianhai Webank entered into a loan agreement to borrow RMB 310,000 (approximated US$43,663) with a fixed annual interest rate at 6.0653%, repay in installment due on December 12, 2025.		42,935			43,663
Subtotal of long-term loans		42,935			43,663
Less: long-term loans - current portion		(24,534	)		(18,713	)
Long-term loans – noncurrent portion	$	18,401		$	24,950

All bank loans the Company borrowed were for the use of working capital in the normal course of ordinary business. For the three months ended March 31, 2024 and 2023, the Company recorded interest expense on bank loans amounted to $11,898 and $16,569, respectively.

14.

OTHER PAYABLES AND ACCRUED LIABILITIES

Other payables and accrued liabilities consisted of the following:

	March 31, 2024		December 31, 2023
Salary payable	$	47,126	$	58,243
Short-term lease payable (1)		38,494		39,147
Accrued operating expenses (2)		73,249		114,759
Other payables		11,069		9,720
	$	169,938	$	221,869

(1)

The Company elected short-term lease accounting policy to record the lease of it plant area which did not recognized right-of-use assets and lease liabilities. The short-term lease payable represents the amount that lease payment was due and outstanding as of the balance sheet day.

(2)

Accrued operating expenses included audit fee, consulting fee, services fee and utilities expenses that incurred in the ordinary course of the company’s operation.

15.

NON-CONTROLLING INTERESTS

The Company had controlling financial interest of YZ JIT, a majority VIE of the Company, which is consolidated in the Company’s financial statements with a non-controlling interest (“NCI”) recognized. The Company held an 85.53% controlling financial interest in YZ JIT as of March 31, 2024 and December 31, 2023.

As of March 31, 2024 and December 31, 2023, NCI in the consolidated balance sheet was ($47,342) and ($23,246), respectively. For the three months ended March 31, 2024, the comprehensive loss attributable to shareholders’ equity and NCI is ($142,572) and ($24,096), respectively. For the three months ended March 31, 2023, the comprehensive income attributable to shareholders’ equity and NCIs is $45,029 and $7,619, respectively.

16.

TAXATION

Income Taxes

United States of America

JRSIS is registered in the State of Florida and is subject to the tax laws of United States of America.

The Company has no tax position at March 31, 2024 for which the ultimate deductibility is highly certain but for which there is uncertainty about the timing of such deductibility. The Company does not recognize interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses. No such interest or penalties were recognized during the period presented. The Company had no accruals for interest and penalties at March 31, 2024. The Company’s utilization of any net operating loss carry forward may be unlikely as a result of its intended activities.

JRSIS HEALTH CARE CORPORATION ITS SUBSIDIARIES

NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

As of March 31, 2024, the operations in the United States of America incurred $23,233,689 of cumulative net operating losses which can be carried forward to offset future taxable income. The net operating loss carryforwards begin to expire in 2044, if unutilized. The Company has provided for a full valuation allowance against the deferred tax assets of $4,879,075 on the expected future tax benefits from the net operating loss carryforwards as the management believes it is more likely than not that these assets will not be realized in the future.

British Virgin Islands (“BVI”)

The Company subsidiaries, JRSIS Health Care Limited, are incorporated in BVI and is not subject to tax on income or capital gain. In addition, payments of dividends by the Company to their shareholders are not subject to withholding tax in the BVI.

Hong Kong

The Company’s subsidiaries, Runteng Medical Group Company Limited, are incorporated in Hong Kong and has no operating profit or tax liabilities during the period. Runteng are subject to tax at 16.5% on the assessable profits arising in or derived from Hong Kong.

The PRC

The Company’s subsidiaries operating in the PRC are subject to the Corporate Income Tax Law of the People’s Republic of China at a unified income tax rate of 25%. The reconciliation of income tax rate to the effective income tax rate for the three months ended March 31, 2024 and 2023 from our continuing operation is as follows:

	For the Three Months Ended March 31,
	2024			2023
Income (loss) before income taxes from PRC operation	$	(169,950	)	$	61,421
Statutory income tax rate		25	%		25	%
Income tax expense (benefit) at statutory rate		(42,487	)		15,355
Tax effect of non-deductible items		-			(4,518	)
Tax effect of non-taxable items		-			11,590
Valuation allowance of deferred tax assets		(42,487	)		-
Income tax expense (benefit)	$	-		$	8,283

Value-Added Tax and Other Withholding and Other Levies

The Company’s goods and services are sold in the PRC and are subject to Value-added tax (“VAT”) on the gross sales price. The VAT rates range from 6% to 13%, depending on the type of goods or services sold. The VAT may be offset by VAT paid by the Company on raw materials and other materials included in the cost of producing or acquiring its finished products. The Company’s subsidiaries in PRC were required to file VAT tax return each month to qualify the VAT paid and calculate VAT payable. The Company recorded a VAT payable net of payments if VAT payable on the gross sales is larger than VAT paid by the Company on purchase of materials or finished goods, on the contrary, the Company recorded VAT deductible in the accompanying financial statements net of any VAT payable at the end of reporting periods.

The Company is also subject to other levies such as stamp tax, unban construction tax, and additional education tax which are charged by local governments. The rate of such levies is small and varies among the different jurisdictions in which the Company does business. The Company also acts as the personal income tax withholding agent for the salaries paid its employees.

JRSIS HEALTH CARE CORPORATION ITS SUBSIDIARIES

NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

The following table provided details of taxes payable as of March 31, 2024 and December 31, 2023:

	March 31, 2024		December 31, 2023
VAT payable	$	39,126	$	15,830
Corporation income tax		-		969
Withholding personal tax		-		176
Other levies		426		1,870
Total taxed payables	$	39,552	$	18,845

17.

EARNINGS PER SHARE

Basic earnings per share is computed using the weighted average number of common shares outstanding during the year. The dilutive effect of potential common shares outstanding is included in diluted earnings per share. The following table sets forth the computation of basic and diluted earnings per share for the three months ended March 31, 2024 and 2023:

	For the Three Months Ended March 31,
	2024			2023
Numerator:
Income (loss) attributable to common shareholders	$	(145,356	)	$	45,446
Denominator:
Weighted average common shares outstanding – Basic and diluted		84,334,314			76,757,439
Income (loss) per shares – basic and diluted	$	(0.002	)	$	0.001

18.

STOCKHOLDERS’ EQUITY

The Company is authorized to issue preferred stock 2,000,000 shares, $0.0001 par value, nil issued and outstanding as of March 31, 2024 and December 2023.

The Company is authorized to issue 100,000,000 shares of common stock, $0.0001 par value. As of November 30, 2023 immediately before the closing of the Reverse Acquisition as described in NOTE 1 - ORGANIZATION AND BUSINESS BACKGROUND, the Company has 5,836,666 shares of common stock issued and outstanding. To affect the closing of the Reverse Acquisition, the Company issued 76,757,439 shares of its common stock to Jumi GCL which is a holding company owned by Linhai Zhu, Yulin IGP and Jumi IIP, who are the beneficial owners of 85.53% of Guangzhou JIE that adopted the underlying Reverse Acquisition, as of March 31, 2024, the common shares issued and outstanding are 84,598,650 shares.

19.

CHINA CONTRIBUTION PLAN

Under the PRC Law, full-time employees of its subsidiaries of the Company in the PRC are entitled to staff welfare benefits including medical care, welfare subsidies, unemployment insurance and pension benefits through a China government-mandated multi-employer defined contribution plan. These benefits are required to accrue for, based on certain percentages of the employees’ salaries. The total contributions made for such employee benefits were approximately $1,462 and $1,442 for the three months ended March 31, 2024 and 2023, respectively.

20.

STATUTORY RESERVES

Under the PRC Law the Company’s subsidiaries and VIE are required to make appropriations to the statutory reserve based on after-tax net earnings which determined in accordance with generally accepted accounting principles of the People’s Republic of China (the “PRC GAAP”). Appropriation to the statutory reserve should be at least 10% of the after-tax net income until the reserve is equal to 50% of the registered capital. The statutory reserve is established for the purpose of providing employee facilities and other collective benefits to the employees and is non-distributable other than in liquidation. The Company’s subsidiaries and VIE have not been made earnings determined in PRC GAAP, there were not any statutory reserves made until March 31, 2024.

JRSIS HEALTH CARE CORPORATION ITS SUBSIDIARIES

NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

21.

CONCENTRATIONS OF RISK

The Company is exposed to the following concentrations of risks:

(a)

Major customers

For the three months ended March 31, 2024, customers accounted for 10% or more of the Company’s total revenue and its related outstanding accounts receivable as at the balance sheets date are presented as follows:

	For Three Months Ended March 31, 2024					March 31, 2024
Customers	Revenue		Percentage of revenue			Accounts receivable
Customer A	$	270,092		54	%	$	(2,071	)
Customer B		157,484		31	%		-
Customer C		65,618		13	%		-
	$	493,194		98	%	$	(2,071	)

For the three months ended March 31, 2023, customers accounted for 10% or more of the Company’s total revenue and its related outstanding accounts receivable as at the balance sheets date are presented as follows:

	For Three Months Ended March 31, 2023					March 31, 2023
Customers	Revenue		Percentage of revenue			Accounts receivable
Customer A	$	458,873		96	%	$	221,537
	$	458,873		96	%	$	221,537

(b)

Major vendors

For the three months ended March 31, 2024, the vendors who accounted for 10% or more of the Company’s total purchases and its outstanding accounts payable balances as at balance sheets, are presented as follows:

	For the three months ended March 31, 2024					March 31, 2024
Vendor	Purchases		Percentage of purchases			Accounts payable
Vendor A	$	163,088		38	%	$	162,615
Vendor B		67,193		16	%		-
Vendor C		65,618		15	%		-
	$	295,899		69	%	$

For the three months ended March 31, 2023, the vendors who accounted for 10% or more of the Company’s total purchases and its outstanding accounts payable balances as at balance sheets, are presented as follows:

	For the three months ended March 31, 2023					March 31, 2023
Vendor	Purchases		Percentage of purchases			Accounts payable
Vendor A	$	282,063		70	%	$	40,876
Vendor B		73,204		18	%		-
	$	355,267		88	%	$	40,876

JRSIS HEALTH CARE CORPORATION ITS SUBSIDIARIES

NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

(c)

Credit risk

Financial instruments that are potentially subject to credit risk consist principally of trade receivables. The Company believes the concentration of credit risk in its trade receivables is substantially mitigated by its ongoing credit evaluation process and relatively short collection terms. The Company does not generally require collateral from customers. The Company evaluates the need for an allowance for doubtful accounts based upon factors surrounding the credit risk of specific customers, historical trends and other information.

(d)

Interest rate risk

As the Company has no significant interest-bearing assets, the Company’s income and operating cash flows are substantially independent of changes in market interest rates.

The Company’s interest-rate risk arises from bank loans. The Company manages interest rate risk by varying the borrowing and maturity dates variable rate debt, limiting the amount of variable rate debt, and continually monitoring the effects of market changes in interest rates. As of March 31, 2024 and 2023, all bank loans were at fixed rates.

(e)

Exchange rate risk

The reporting currency of the Company is US$, to date the majority of the revenue and costs are denominated in RMB and a significant portion of the assets and liabilities are denominated in RMB. As a result, the Company is exposed to foreign exchange risk as its revenue and results of operations may be affected by fluctuations in the exchange rate between US$ and RMB. If RMB depreciates against US$, the value of RMB revenue and assets as expressed in US$ financial statements will decline. The Company does not hold any derivative or other financial instruments that expose to substantial market risk.

(f)

Economic and political risks

The Company’s operations are conducted in the PRC. Accordingly, the Company’s business, financial condition and results of operation may be influenced by the political, economic and legal environment in the PRC, and by the general state of the PRC economy. The slowdown of the growth of the PRC’s economy might has adversely effects on our current business and future developments if we would not catch the opportunities of the increasing demand of intelligent machine from the development of the general social economy.

The Company’s operations in the PRC are subject to special considerations. These include risks associated with, among others, the political, economic and legal environment and foreign currency exchange. The Company’s results may be adversely affected by changes in the political and social conditions in the PRC, and by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion, remittances abroad, and rates and methods of taxation.

22.

SUBSEQUENT EVENTS

The Company evaluates subsequent events that have occurred after the balance sheet date but before the financial statements are issued. Subsequent to the date the financial statements were filed, there was no subsequent event that would require disclosure to or adjustment to the financial statements.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

The following discussion should be read in conjunction with our unaudited consolidated financial statements and the notes thereto included elsewhere in this report.

In addition to historical information, the discussion in this section of this report contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those discussed herein. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in this section, those discussed in “Risk Factors” and those discussed elsewhere in our report on Form 10-K which filed on May 26, 2024.

We caution readers not to place undue reliance on any forward-looking statements made by us, which speak only as of the date they are made. We disclaim any obligation, except as specifically required by law and the rules of the SEC, to publicly update or revise any such statements to reflect any change in our expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

OVERVIEW

Company Structure

JRSIS Health Care Corporation (the “Company” or “JRSIS”) was incorporated on November 20, 2013 under the laws of the State of Florida. Through its 100% held subsidiary JRSIS Health Care Limited (“JRSIS-BVI”), a limited liability company registered in British Virgin Island (“BVI”), it holds 100% shares of Runteng Medical Group Co., Ltd (“Runteng”), a limited liability company registered in Hong Kong. On April 12, 2022, Runteng organized and owned 100% of the equity in Laidian Technology (Zhongshan) Co., Ltd (“Laidian”), a wholly foreign-owned enterprise (“WFOE”) subsidiary registered under the law of the People’s Republic of China (“the PRC”) in Zhongshan City, Guangdong Province.

Until March 31, 2022, Runteng also owned 70% of the equity in Harbin Jiarun Hospital Co., Ltd (“Jiarun”), a for-profit hospital incorporated in Harbin City of Heilongjiang, the People’s Republic of China (“the PRC”) and was fully disposed of on April 1, 2022.

On November 30, 2023, the Company, through its subsidiary Laidian, completed an acquisition transaction that resulted the Company obtained 85.53% variable interest in Yongzhou Jumi Intelligent Technology Co., Ltd. (“Yongzhou JIT”). For a detail description of our corporate structure and contractual arrangements and its related risks, see “ITEM 1 Business” in PART I elsewhere in Form 10-K filed on May 26, 2024. The transaction represents a “Reverse Acquisition” rather than a business combination that Yongzhou JIT is deemed to be the accounting acquirer in the transaction and is being accounted for as a reverse acquisition and recapitalization.

Management’s discussion and analysis in this section was based on the historic financial information of Yongzhou JIT as accounting acquirer. Those financial statements represent that the assets and liabilities and the operations that reflected the historical financial statements for periods prior to the Reverse Acquisition of Yongzhou JIT and will be recorded at the carrying amount basis of Yongzhou JIT, and the consolidated financial statements after the Reverse Acquisition included the assets and liabilities of the Company and Yongzhou JIT, and the historical operations of Yongzhou JIT and operations of the Combined Company from the date of Reverse Acquisition.

Technology and Innovation

We, through Yongzhou JIT, commitment to technological advancement and delivering cutting-edge intelligent machine and system solutions, especially for One-stop smart medicine distribution program and new retail intelligent terminal solution to meet the evolving needs of its customers. Yongzhou JIT master intelligent algorithms and techniques, intelligent terminal technologies and moving communication related technology.

As of the date of this report, Yongzhou JIT owns 2 patents for invention, 16 patents for utility models, 7 design patents and 21 software copyrights in the PRC. In addition, there several invention patents under the processing of substantive examination stage of authorities. All the core patented technologies and models of patents and copyright have been applied into the Company’s products and services. The Company had established a research and development team of experts consisting of about 10 more persons, which accounted for about 25% total employee of Yongzhou JIT. After years of efforts, the Company holds an outstanding position in the field of intelligent medicine products areas around PRC. In addition, to promote research and innovation in intelligent medicine areas, the Company actively collaborates with several prominent research institutions and universities, such as Hunan Institute Technology, to keep our intelligent techniques being updated in advanced.

Products and Services, Customers

Based on techniques we controlled and our plants and equipment we operated in China, we can provide our customers with services to customize cloud-based hardware and the relevant system/software, open platform of software as a service, cloud-based vending equipment, one-stop cloud-based medicine equipment (including automated drug sales, remote consultations, unmanned pharmacies) and a series of remote intelligent terminal products. We, currently, are engaging in the business of developing intelligent technology related to medical and producing and sales equipment based on its technology. We also provide services to design, develop, install, and maintain the cloud-based systems for our customers.

Currently, all our operations are conducted in the People’s Republic of China (“the PRC”). Our customers of our products and service included: a) governmental projects: such as local government’s healthcare project to up-grate its smart medical insurance, intelligent epidemic prevention measures, intelligent service on remote physical examination, health testing, remote consultation, prescription, payments and medicine delivery etc.; b) Hospital projects: such as a smart application system in hospital for collecting the drug information from each out-patient and direct the pharmacies in the hospital to prepare the dug for the out-patient and guide the put-patient to the right window to take his/her medicine; c) pharmacies outside the hospital and e) entities in health industry, such as the internet service platform; f) other intelligent service providers. Our products and services might be applied in more and more areas along with the development of technology and manufacturing.

GOING CONCERN UNCERTAINTIES

The continuation of the Company as a going concern through the next twelve months is dependent upon (1) the continued financial support from its external financing, including bank loans and issuance of its shares to potential shareholders. Management believes that it can obtain additional bank loans and the issuance of common shares of the Company is available if the Company effort to do so, and (2) further implement management’s business plan to extend its operations and generate sufficient revenue and cash flows to meet its obligations. The Company’s operation is on the upward trend, and management believes that the Company’s operation can generate enough revenue and cash to meet its obligation in the normal course of business. While the Company believes in the viability of its strategy to increase sales volume and in its ability to raise additional funds, there can be neither any assurances to that effect, nor any assurance that the Company will be successful in securing sufficient funds to sustain the operations.

Management believes that the actions presently being taken to obtain additional funding and implement its strategic plan provide the opportunity for the Company to continue as a going concern.

CRITICAL ACCOUNTING POLICIES

Our discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. On an on-going basis, we evaluate our estimates and judgments, including those related to revenue recognition, receivable, inventory, leases, and accrued expenses. We base our estimates on historical experience, known trends and events and various other factors that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. Changes in estimates are recorded in the period in which they become known.

Please refer to our significant accounting policies in Note 3 to our unaudited consolidated financial statements included elsewhere in this report. We believe those accounting policies affect our more significant judgments and estimates used in the preparation of our consolidated financial statements.

RESULTS OF OPERATIONS

Comparison of the three months ended March 31, 2024 and 2023

	For the three months ended March 31, 2024						For the three months ended March 31, 2023						Amount
	Amount			% of Revenue			Amount			% of Revenue			increase (decrease)			% increase (decrease)
Revenue	$	500,420			100	%	$	476,994			100	%	$	23,426			5	%
Cost of revenue		443,198			89	%		325,602			68	%		117,596			36	%
Gross profit		57,222			11	%		151,392			32	%		(94,170	)		(62	)%
Operating expenses		218,128			44	%		73,868			15	%		144,260			195	%
Other income (loss), net		(9,042	)		(2	)%		(16,106	)		(3	)%		7,064			(44	)%
Income (loss) before income tax		(169,948	)		(34	)%		61,418			13	%		(231,366	)		(377	)%
Income tax expense		-			0	%		8,283			2	%		(8,283	)		(100	)%
Net loss from operations		(169,948	)		(34	)%		53,135			11	%		(223,083	)		(420	)%
Less: non-controlling interest		(24,592	)		(5	)%		7,689			2	%		(32,281	)		(420	)%
Net loss attributable to the Company	$	(145,356	)		(29	)%	$	45,446			10	%	$	(190,802	)		(420	)%

Revenue

Total revenue for the three months ended March 31, 2024 were $500,420, increased $23,426, or approximately 5%, as compared to total revenue for the three months ended March 31, 2023 of $476,994. The increase of revenue due to the increase volumes of goods sold and services provided. We have taken more aggressive measures in our marketing and promotion efforts to improve our sales performance since the beginning of 2024. We initially expected that the demand for our products and services in the market is expected to rapid growth. However, macroeconomic and social demand in the PRC is far less robust than it was expected in the wake of the COVID-19 pandemic. We commit to iterate and update continuously our products and services with our developing technology and we expected that our revenue will continue to grow along with our marketing effort and upgrading of our product in the foreseeable future, the grow of our revenue also depends on the microeconomic and social demand in the PRC.

Currently, the Company’s revenue generates from two sources, including 1) sales of goods of intelligent terminal, such as medicine vending machine, that the Company self-manufactured and assembled in its plant, and 2) services rendered, such as installment and maintenance terminal system, designing and development of intelligent system to its customers. Goods and services that the Company transferred to its customers deriving its revenue are all based on the Company’s technology and patents.

The Company derived its revenue from both third-party customers and related party. Guangzhou JIE, the legal parent of Yongzhou JIT in the PRC and both under the common control of Linhai Zhu, the CEO of the Company, generally purchases certain machine from Yongzhou JIT and resales to its customers, and also had Yongzhou JIT to provided instalment and maintenance service for its customers from time to time and pays case by case under a negotiated range of charge rate to Yongzhou JIT. Please refer to related notes to financial statements elsewhere in the report for more information related to the related party transactions. Ending customers of the Company’s goods and services mainly includes medicine service organization, business entities and local government.

Cost of revenue

Cost of revenue for the three months ended March 31, 2024 was $443,198, increased $117,596, approximately 36%, as comparable to cost of revenue for the three months ended March 31, 2023 of $325,602. In addition to the increase volume of products sold and services rendered, the increase of the cost of revenue also resulted in increasing of cost of labor cost, especially, the cost of revenue from our technology service mainly consist of labor cost to fulfill our services obligations. Cost of revenue consists primarily of the cost of the machine sold and incremental cost to fulfil the contracts with customers.

Gross profit

Gross profit for the three months ended March 31, 2024 was $57,222, decreased $94,170, decreased approximately 62%, as comparable to the same period March 31, 2023 of $151,392. The gross margin was 11% for the three months ended March 31, 2024 decreased from 32% for the same period ended March 31, 2023. The factors result in decrease both in gross profit and it margin mainly included: 1) the microeconomic performance fell short of the management expectations and the overall social demand was not strong enough, to promote the revenue during the three months ended March 31, 2024, the Company had to made discount to obtain contracts with customers, which decreased unit price as compared to the same period of 2023; 2) On the other hand, the cost of revenue was increased due to the increase of labor cost related to our revenue as stated in preceding paragraph. The Company could not expect whether it will continue to make discount to promote it marketing activities and if labor cost of its product and services will continue to increase or decrease in the foreseeable future.

Operating expenses

Operation expenses consist mainly of research and development, marketing and advertising, logistics, auditing and legal service, other professional service and listing support fees, employee salary, depreciation and amortization, office rental fee and utilities of underlying not associated with production that otherwise recorded as cost of inventories.

Operating expenses for the three months ended March 31, 2024 were $218,128, as compared to $73,868 for the three months ended March 31, 2023, an increase of $144,260, or increase approximately 195%. As compared to the same period s as of March 31, 2023, during the three months ended March 31, 2024, our selling expense increased approximated $ 94,421 and our general and administrative expenses increased approximated $69,880 and our research and development expenses decreased approximated $20,041. The fact that the Company reduced its research and development expenditures for the three months ended March 31, 2024 is because the Company re-organized and simplified its research team to save cost without reducing efficiency of research and development. The Company insisted in an on-going reorganization to optimize its expenditures to respond its deficiency of working capital and make profits. The Company expects to invest more capital in its research and development activities as its the financial condition gets better. The increase of selling expenses for the three months ended March 31, 2024 as compared to the same period of prior year, mainly result from the increase of the marketing and advertising activities in current period. The increase of the general and administrative expense for the three months ended March 31, 2024 mainly resulted from the increasing of the professional services and related listing fees, which without such expense for the same period of prior year.

Other income (loss), net

Other income mainly consists of: 1) non-capitalized interest expense accrued form bank loans used for working capital; 2) gain or loss on disposal of inventories, equipment and other assets; and 3) government subsidy on tax exemption. For the three months ended March 31, 2024 the Company reported other loss of $9,042, as compared to other net loss $16,106 for the three months March 31, 2023, a decrease of $7,064, or decreased approximately 44%. The decrease in other net loss for the three months ended March 31, 2024 as compared to the same period of prior year mainly resulted non-capitalized interest expense for bank loan decreased of approximated $7,832 due to the reduction of bank loans.

Net income (loss)

We reported net loss of ($169,948) for the three months ended March 31, 2024, as compared to net income $53,135 for the three months ended March 31, 2024, which turned from gain to loss and the net loss represent an increase of $233,083, or increased approximated of 420%.

LIQUIDITY AND CAPITAL RESOURCES

Liquidity is the ability of a company to generate funds to support its current and future operations, satisfy its obligations and otherwise operate on an ongoing basis. At March 31, 2024, we had cash of $323,611 and a working capital deficit of $581,125 as compared to cash of $4,638 and a working capital deficit of $373,856 at March 31, 2023.

To date, the Company has financed our operating and investing activities mainly through cash generated from our business and borrowings from financial institutions and contributions from shareholders. We had plan to issue our common shares to finance more cash for to supplement our working capital. We plan to finance our business under our management measures and financing policy along with our current financing resources. We did not identify any material capital expenditures requirements at the date of this report, but we were not sure that our cash on hand will be sufficient to meet our current and anticipated needs for general corporate purposes for at least the next 12 months. As management measures and financing policies, we will continue to delay payment and accelerate collection in our operations, optimization and reducing expenses to overcome cash deficit in our normal course of business in the foreseeable future. Even though, we may, however, need additional cash resources in the future if we experience changes in business conditions or other developments. We may also need additional cash resources in the future if we find and wish to pursue opportunities for investment, acquisition, capital expenditure or similar actions. If we determine that our cash requirements exceed the amount of cash we have on hand, we may seek to issue equity or equity-linked securities or obtain debt financing including additional bank loans. The issuance and sale of additional equity would result in further dilution to our shareholders. The incurrence of indebtedness would result in increased fixed obligations and could result in operating covenants that would restrict our operations. We cannot assure you that financing will be available in amounts or on terms acceptable to us, if at all.

The following is a summary of cash provided by or used in each of the indicated types of activities for the three months ended March 31, 2024 and 2023, respectively.

	For the Three Months Ended March 31,
	2024			2023
Net cash provided by (used in) operating activities	$	(204,937	)	$	(16,507	)
Net cash provided by (used in) investing activities		-			-
Net cash provided by (used in) financing activities		413,267			(143,175	)
Exchange rate effect on cash		(2,833	)		5,507
Net cash inflow (outflow) for the periods	$	205,497		$	(154,175	)

Operating Activities

Net cash used in our operating activities for the three months ended March 31, 2024 was $204,937, as compared to net cash used in operating activities of $16,507 for the three months ended March 31, 2023. Net cash used in our operating activities for the three months ended March 31, 2024 was attributable to net loss of $169,948 for the period and was primarily adjusted by non-cash items such as (1) an aggregate total of $1,091 from right-of used assets amortization expenses and interest expenses accrual of lease liabilities of operating leases during the first quarter of 2024, (2) depreciation and amortization expenses of long-lived assets of $12,197 for the three months ended March 31, 2024, (3) an aggregate gain of $412 from disposal of impaired inventories. Net operating inflows for the three months ended March 31, 2024 resulted primarily from the following factors: 1) accounts receivable collected from both third parties and related parties amount to $118,933; 2) a decrease of advance to suppliers of $89,181 due to receipt of inventories from venders; 3) a decrease of inventories $2,571 due to increase of goods sold, 4) advance from customers increased of $8,486 due to cash collected in according with the term of certain service contacts which services without completely delivery as of March 31, 2024; 5) taxes payable increased by $21,115 mainly due to the Company delayed the payments of VAT payable. Cash inflow was offset by the following outflows factors: 1) prepayments and other receivable increased by $13,414 due to the increase of VAT deductibles as of March 31, 2024, 2) account payable both to third parties and related parties decreased aggregate by $225,202; 3) cash paid for operation lease of $1,091 and 4) Other payables and accrued liabilities decreased by $48,444 due to the Company made more payments for listing professional expense during the period.

Net cash used in our operating activities for the three months ended March 31, 2023 was $16,507. This was attributable to net income $53,135 for the three months ended March 31, 2023 and was primarily adjusted by non-cash items such as (1) an aggregate total of $1,141 from right-of used assets amortization expenses and interest expenses accrual of lease liabilities of operating leases for the first quarter of 2023, (2) depreciation and amortization expenses of long-lived assets of $14,403 for the three months ended March 31, 2023, and (3) deferred income tax decrease of $4,613. Net operating inflows for the three months ended March 31, 2023 resulted primarily from the following factors: 1) accounts receivable from third parties decreased by $246,259 due to more cash collected from customers; 2) accounts payable to related parties increased by $37,374 due to delay payment for the purchase from related parties; and 3) other payable and accrued liabilities increased by $18,944 due the Company delay payment for it utility. Cash inflow was offset by the following outflows factors: 1) accounts receivable from related parties increased by $144,085 and advances from customers decreased by $62,688 due to the payment was delayed from customers during this period; 2) inventories increased by $145,871 due to the preparation for future goods sold; 3) advances to suppliers increased by $62,688 and prepaid expenses and other receivables increased by $524 and accounts payable to third parties decreased by $14,903 due to the Company make more payments at March 31, 2023; 4) advances from customers decreased by $3,136 due to revenue recognized from those advances; 5) Taxes payable decreased by $12,680 representing the payable of taxes both corporation income tax and VAT; 6) cash paid for operation lease liabilities of $2,287.

Investing Activities

There was no cash provided or used in investing activities for the three months ended March 31, 2024 and 2023, respectively.

Financing Activities

Net Cash provided by our financing activities for the three months ended March 31, 2024 was $413,267. For the three months ended March 31, 2024, we received cash from issuance of common shares of $20,045, proceeds from bank loans of $403,422, we also had net amount of $10,200 used in financing purpose between the Company and its related parties.

Net cash used our financing activities from the three months ended March 31, 2023 was ($143,175). For the three months ended March 31, 2023, we repaid bank loan of $166,210 and had net amount of $23,035 provided by financing purpose between the Company and its related parties.

Inflation

We believe that the relatively moderate rate of inflation over the past few years has not had a significant impact on our results of operations.

OFF-BALANCE SHEET ARRANGEMENTS

We do not have any material off-balance sheet arrangements.

IMPACT OF RECENTLY ISSUED NEW ACCOUNTING STANDARDS

We do not expect the adoption of recently issued accounting pronouncements to have a significant impact on our results of operations, financial position or cash flow.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Pursuant to Item 305(e) of Regulation S-K (§ 229.305(e)), the Company is not required to provide the information required by this Item as it is a “smaller reporting company,” as defined by Rule 229.10(f)(1).

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

The Company’s management is responsible for establishing and maintaining adequate internal control over our financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act. Internal control over financial reporting is a process to provide reasonable assurance regarding the reliability of the Company’s financial reporting for external purposes in accordance with generally accepted accounting principles. Internal control over financial reporting includes policies and procedures that: (i) pertain to maintaining records that in reasonable detail accurately and fairly reflect the Company’s transactions; (ii) provide reasonable assurance that transactions are recorded as necessary for preparation of the Company’s financial statements and that receipts and expenditures of company assets are made in accordance with management authorization; and (iii) provide reasonable assurance that unauthorized acquisition, use or disposition of company assets that could have a material effect on our financial statements would be prevented or detected on a timely basis.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies and procedures may deteriorate.

The Company’s management is also required to assess and report on the effectiveness of the Company’s internal control over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act of 2002 (“Section 404”). We conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as such term is defined under Rule 13a-15(e) promulgated under the Securities Exchange Act of 1934, as amended (Exchange Act), under the supervision of and with the participation of our management, including the Chief Executive Officer and Chief Financial Officer. Based on that evaluation and the identification of a material weakness in internal control over financial reporting described below, our management, including the Chief Executive Officer and Chief Financial Officer, concluded that as of the end of the period covered by this report the Company’s disclosure controls and procedures were not effective:

●

The relatively small number of employees who are responsible for accounting functions prevents us from segregating duties within our internal control system. The Company may engage more employees when more financial resources are available.

●

Our internal financial staff lack expertise in identifying and addressing complex accounting issued under U.S. Generally Accepted Accounting Principles. Currently, we are relying on external consultants to assist us complying with the US GAAP financial reporting process.

●

We are trying to improve our documentation system concerning our existing financial processes, risk assessment and internal controls so as to provide sufficient and adequate records for the preparation and disclosure of financial reporting process. Currently, we are relying on external consultants to assist us complying with the financial reporting process.

●

We do not presently have an audit committee. JRSIS will setup an audit committee when more financial resources are available.

Management’s Remediation plan

While management believes that the Company’s financial statements previously filed in the Company’s SEC reports have been properly recorded and disclosed in accordance with US GAAP, based on the material weakness in our internal control over financial reporting identified above, we have designed and plan to implement, or in some cases have already implemented, the specific remediation initiatives described below:

The Company is currently looking for an outside consultant with considerable public company reporting experience and breadth of knowledge of US GAAP to provide more training in connection with the preparation and review of its financial statements to the employees.

Changes in Internal Control over Financial Reporting

Subject to the foregoing disclosure, there were no changes in our internal control over financial reporting during the three months ended March 31, 2024 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II — OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS.

None

ITEM 1A. RISK FACTORS

As of the date of this filing, there have been no material changes from the risk factors disclosed in Part I, Item 1A (Risk Factors) contained in our Annual Report on Form 10-K for the year ended December 31, 2023. We operate in a changing environment that involves numerous known and unknown risks and uncertainties that could materially affect out operations. The risks, uncertainties and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2023 may cause our actual results, performances and achievements to be materially different from those expressed or implied by our forward-looking statements. If any of these risks or events occurs, our business, financial condition or results of operations may be adversely affected.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

None

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION.

None.

ITEM 6. EXHIBITS.

The list of Exhibits required by Item 601 of Regulation S-K to be filed as a part of this Form 10-Q are set forth on the Exhibit Index immediately preceding such Exhibits and is incorporated herein by this reference.

Exhibit Number	Description	Incorporated by Reference to
31.1	Rule 13(a)-14(a)/15(d)-14(a) Certification of Principal Executive Officer
31.2	Rule 13(a)-14(a)/15(d)-14(a) Certification of Principal Financial Officer
32.1	Section 1350 Certification of Principal Executive Officer
32.2	Section 1350 Certification of Principal Financial Officer
101.INS	Inline XBRL Instance Document
101.SCH	Inline XBRL Taxonomy Extension Schema Document
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document
104	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	JRSIS HEALTH CARE CORPORATION
	(Registrant)

Date: May 29, 2024	By:	/s/ Linhai Zhu
		Linhai Zhu
		Chairman of the board,
		Chief Executive Officer,
		Chief Financial Officer

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, this Report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

Signature	Title	Date

/s/ Linhai Zhu	Chairman of the Board, Chief Executive Officer,	May 29, 2024
Linhai Zhu	Chief Financial Officer

/s/ Zhuowei Zhong	Director	May 29, 2024
Zhuowei Zhong

NONE 76757439 84334314 0.001 0.002 76757439 84334314 0.001 0.002 false --12-31 Q1 0001597892 0001597892 2024-01-01 2024-03-31 0001597892 2024-03-31 0001597892 2023-12-31 0001597892 us-gaap:RelatedPartyMember 2024-03-31 0001597892 us-gaap:RelatedPartyMember 2023-12-31 0001597892 2023-01-01 2023-03-31 0001597892 us-gaap:CommonStockMember 2022-12-31 0001597892 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001597892 us-gaap:RetainedEarningsMember 2022-12-31 0001597892 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001597892 us-gaap:NoncontrollingInterestMember 2022-12-31 0001597892 2022-12-31 0001597892 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001597892 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0001597892 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0001597892 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-12-31 0001597892 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-12-31 0001597892 2023-01-01 2023-12-31 0001597892 us-gaap:CommonStockMember 2023-12-31 0001597892 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001597892 us-gaap:RetainedEarningsMember 2023-12-31 0001597892 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001597892 us-gaap:NoncontrollingInterestMember 2023-12-31 0001597892 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001597892 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001597892 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001597892 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001597892 us-gaap:NoncontrollingInterestMember 2024-01-01 2024-03-31 0001597892 us-gaap:CommonStockMember 2024-03-31 0001597892 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001597892 us-gaap:RetainedEarningsMember 2024-03-31 0001597892 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001597892 us-gaap:NoncontrollingInterestMember 2024-03-31 0001597892 2023-03-31 0001597892 jrss:JRSISHealthCareLimited1Member 2013-12-31 0001597892 jrss:RuntengMedicalGroupCoLtdMember 2012-09-17 0001597892 jrss:RuntengOwnsHarbinJiarunHospitalCoLtdMember 2022-03-31 0001597892 jrss:JunshengZhangMember 2022-03-31 0001597892 jrss:JiarunToZhangJunshengMember 2022-04-28 0001597892 jrss:JiarunZhangJunshengMember 2022-04-28 0001597892 2022-04-28 2022-04-28 0001597892 jrss:LaidianTechnologyZhongshanCoLtdMember 2022-04-12 0001597892 jrss:YongzhouJITMember 2023-11-30 0001597892 jrss:ExclusiveBusinessCooperationAgreementMember jrss:ZhongZhuoweiMember 2024-03-31 0001597892 jrss:YongzhouJITMember 2024-03-31 0001597892 jrss:ExclusiveBusinessCooperationAgreementMember jrss:GuangzhouJIEMember 2024-03-31 0001597892 jrss:ManagementArrangementMember 2024-03-31 0001597892 jrss:EquityInterestPledgeAgreementMember jrss:GuangzhouJIEMember 2024-03-31 0001597892 jrss:ExclusiveOptionAgreementMember jrss:YongzhouJITMember 2024-03-31 0001597892 jrss:ManagementAgreementsMember jrss:YongzhouJITMember 2024-03-31 0001597892 jrss:JumiGCLMember 2024-03-31 0001597892 jrss:GuangzhouJIEMember 2024-03-31 0001597892 jrss:JRSISMember 2024-03-31 0001597892 jrss:JRSISHealthCareCorporationJRSISMember 2024-01-01 2024-03-31 0001597892 jrss:JRSISHealthCareLimitedJRSISBVIMember 2024-01-01 2024-03-31 0001597892 jrss:RuntengMedicalGroupCompanyLimitedRuntengOrRTMember 2024-01-01 2024-03-31 0001597892 jrss:LaidianTechnologyZhongshanCoLtdLaidianMember 2024-01-01 2024-03-31 0001597892 jrss:YongzhouJumiIntelligentTechnologyCoLtdYongzhouJITOrYZJITMember 2024-01-01 2024-03-31 0001597892 jrss:OwnersMember 2024-03-31 0001597892 srt:MinimumMember 2024-01-01 2024-03-31 0001597892 srt:MaximumMember 2024-01-01 2024-03-31 0001597892 srt:MinimumMember jrss:ProductionLineAndEquipmentMember 2024-03-31 0001597892 srt:MaximumMember jrss:ProductionLineAndEquipmentMember 2024-03-31 0001597892 jrss:ProductionLineAndEquipmentMember 2024-03-31 0001597892 srt:MinimumMember us-gaap:OfficeEquipmentMember 2024-03-31 0001597892 srt:MaximumMember us-gaap:OfficeEquipmentMember 2024-03-31 0001597892 us-gaap:OfficeEquipmentMember 2024-03-31 0001597892 srt:MinimumMember us-gaap:VehiclesMember 2024-03-31 0001597892 srt:MaximumMember us-gaap:VehiclesMember 2024-03-31 0001597892 us-gaap:VehiclesMember 2024-03-31 0001597892 jrss:UtilityModelMember 2024-03-31 0001597892 us-gaap:CopyrightsMember 2024-03-31 0001597892 jrss:YZJITMember 2024-01-01 2024-03-31 0001597892 jrss:JRSISMember 2024-01-01 2024-03-31 0001597892 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember 2024-01-01 2024-03-31 0001597892 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember 2024-03-31 0001597892 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember 2023-12-31 0001597892 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember us-gaap:RelatedPartyMember 2024-03-31 0001597892 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember us-gaap:RelatedPartyMember 2023-12-31 0001597892 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2024-01-01 2024-03-31 0001597892 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2023-01-01 2023-03-31 0001597892 us-gaap:InventoriesMember 2024-01-01 2024-03-31 0001597892 us-gaap:InventoriesMember 2023-01-01 2023-03-31 0001597892 jrss:ProductionLineAndEquipmentMember 2023-12-31 0001597892 us-gaap:OfficeEquipmentMember 2023-12-31 0001597892 us-gaap:TransportationEquipmentMember 2024-03-31 0001597892 us-gaap:TransportationEquipmentMember 2023-12-31 0001597892 jrss:UtilityModelMember 2023-12-31 0001597892 jrss:CopyrightMember 2024-03-31 0001597892 jrss:CopyrightMember 2023-12-31 0001597892 jrss:DormitoryLease2022Member 2022-10-31 0001597892 2022-10-31 0001597892 2022-10-31 2022-10-31 0001597892 jrss:GoodsSoldDirectlyToThirdPartiesMember 2024-01-01 2024-03-31 0001597892 jrss:GoodsSoldDirectlyToThirdPartiesMember 2023-01-01 2023-03-31 0001597892 jrss:GoodsSoldToRelatedPartiesMember 2024-01-01 2024-03-31 0001597892 jrss:GoodsSoldToRelatedPartiesMember 2023-01-01 2023-03-31 0001597892 jrss:TotalRevenueFromGoodsSoldMember 2024-01-01 2024-03-31 0001597892 jrss:TotalRevenueFromGoodsSoldMember 2023-01-01 2023-03-31 0001597892 jrss:ServiceRenderedDirectlyToThirdPartiesMember 2024-01-01 2024-03-31 0001597892 jrss:ServiceRenderedDirectlyToThirdPartiesMember 2023-01-01 2023-03-31 0001597892 jrss:ServiceRenderedToRelatedPartiesMember 2024-01-01 2024-03-31 0001597892 jrss:ServiceRenderedToRelatedPartiesMember 2023-01-01 2023-03-31 0001597892 jrss:TotalRevenueFromServiceRenderedMember 2024-01-01 2024-03-31 0001597892 jrss:TotalRevenueFromServiceRenderedMember 2023-01-01 2023-03-31 0001597892 jrss:TotalCostOfRevenueFromGoodsSoldMember 2024-01-01 2024-03-31 0001597892 jrss:TotalCostOfRevenueFromGoodsSoldMember 2023-01-01 2023-03-31 0001597892 jrss:TotalCostOfRevenueFromServiceRenderedMember 2024-01-01 2024-03-31 0001597892 jrss:TotalCostOfRevenueFromServiceRenderedMember 2023-01-01 2023-03-31 0001597892 us-gaap:RelatedPartyMember 2024-01-01 2024-03-31 0001597892 us-gaap:RelatedPartyMember 2023-01-01 2023-03-31 0001597892 jrss:BankOfChinaMember 2023-03-31 0001597892 jrss:PostalSavingsBankOfChinaMember 2023-03-31 0001597892 jrss:ChinaConstructionBankMember 2024-03-31 0001597892 jrss:BankOfChinaMember 2024-03-31 0001597892 jrss:GuangzhouJumiIntelligentEquipmentCoLtdGuangzhouJIEMember 2024-01-01 2024-03-31 0001597892 jrss:KangmiYaolianGuangzhouWulinwangCoLtdMember 2024-01-01 2024-03-31 0001597892 jrss:ShanghaiJiuchenbengouInformationAndTechnologyCoLtdMember 2024-01-01 2024-03-31 0001597892 jrss:YongzhouJingmiHealthTechnologyCoLtdMember 2024-01-01 2024-03-31 0001597892 jrss:LinhaiZhuHisSpouseMeiLiuMember 2024-01-01 2024-03-31 0001597892 jrss:ZhuoweiZhongMember 2024-01-01 2024-03-31 0001597892 jrss:LugengZhouMember 2024-01-01 2024-03-31 0001597892 us-gaap:RelatedPartyMember jrss:GuangzhouJumiIntelligentEquipmentCoLtdMember 2024-03-31 0001597892 us-gaap:RelatedPartyMember jrss:GuangzhouJumiIntelligentEquipmentCoLtdMember 2023-12-31 0001597892 us-gaap:RelatedPartyMember jrss:KangmiYaolianGuangzhouWulinwangCoLtdMember 2024-03-31 0001597892 us-gaap:RelatedPartyMember jrss:KangmiYaolianGuangzhouWulinwangCoLtdMember 2023-12-31 0001597892 us-gaap:RelatedPartyMember jrss:ShanghaiJiuchenbengouInformationAndTechnologyCoLtdMember 2024-03-31 0001597892 us-gaap:RelatedPartyMember jrss:ShanghaiJiuchenbengouInformationAndTechnologyCoLtdMember 2023-12-31 0001597892 us-gaap:RelatedPartyMember jrss:YongzhouJingmiHealthTechnologyCoLtdMember 2024-03-31 0001597892 us-gaap:RelatedPartyMember jrss:YongzhouJingmiHealthTechnologyCoLtdMember 2023-12-31 0001597892 us-gaap:RelatedPartyMember 2024-03-31 0001597892 us-gaap:RelatedPartyMember 2023-12-31 0001597892 us-gaap:RelatedPartyMember jrss:LugengZhouMember 2024-03-31 0001597892 us-gaap:RelatedPartyMember jrss:LugengZhouMember 2023-12-31 0001597892 us-gaap:RelatedPartyMember us-gaap:RelatedPartyMember 2024-03-31 0001597892 us-gaap:RelatedPartyMember us-gaap:RelatedPartyMember 2023-12-31 0001597892 us-gaap:RelatedPartyMember jrss:LinhaiZhuMember 2024-03-31 0001597892 us-gaap:RelatedPartyMember jrss:LinhaiZhuMember 2023-12-31 0001597892 us-gaap:RelatedPartyMember jrss:ZhuoweiZhongMember 2024-03-31 0001597892 us-gaap:RelatedPartyMember jrss:ZhuoweiZhongMember 2023-12-31 0001597892 jrss:BankOfChinaMember us-gaap:ShortTermDebtMember 2024-03-31 0001597892 jrss:BankOfChinaMember us-gaap:ShortTermDebtMember 2023-12-31 0001597892 jrss:BankOfChinaMember us-gaap:ShortTermDebtMember 2023-06-01 2023-06-30 0001597892 jrss:ChinaConstructionBankMember us-gaap:ShortTermDebtMember 2024-03-31 0001597892 jrss:ChinaConstructionBankMember us-gaap:ShortTermDebtMember 2023-12-31 0001597892 jrss:ChinaConstructionBankMember us-gaap:ShortTermDebtMember 2022-08-01 2022-08-31 0001597892 jrss:YZJITMember us-gaap:ShortTermDebtMember 2023-01-01 2023-12-31 0001597892 jrss:YZJITMember us-gaap:ShortTermDebtMember 2022-08-01 2022-08-31 0001597892 us-gaap:ShortTermDebtMember 2022-08-01 2022-08-31 0001597892 jrss:IndustrialAndCommercialBankOfChinaMember us-gaap:ShortTermDebtMember 2024-03-31 0001597892 jrss:IndustrialAndCommercialBankOfChinaMember us-gaap:ShortTermDebtMember 2023-12-31 0001597892 jrss:IndustrialAndCommercialBankOfChinaMember us-gaap:ShortTermDebtMember 2024-03-05 2024-03-05 0001597892 us-gaap:ShortTermDebtMember 2024-03-31 0001597892 us-gaap:ShortTermDebtMember 2023-12-31 0001597892 jrss:ShenzhenQianhaiWebankMember 2024-03-31 0001597892 jrss:ShenzhenQianhaiWebankMember 2023-12-31 0001597892 jrss:ShenzhenQianhaiWebankMember 2023-01-01 2023-12-31 0001597892 jrss:YZJITMember 2024-03-31 0001597892 jrss:YZJITMember 2023-12-31 0001597892 country:US 2024-03-31 0001597892 country:HK 2024-01-01 2024-03-31 0001597892 us-gaap:PreferredStockMember 2024-03-31 0001597892 us-gaap:PreferredStockMember 2023-12-31 0001597892 jrss:YongzhouJITMember 2023-11-30 0001597892 jrss:JumiGCLMember 2023-11-30 2023-11-30 0001597892 jrss:GuangzhouJIEMember 2023-11-30 0001597892 jrss:CustomerAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-03-31 0001597892 jrss:CustomerAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-03-31 0001597892 jrss:CustomerBMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-03-31 0001597892 jrss:CustomerBMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-03-31 0001597892 jrss:CustomerCMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-03-31 0001597892 jrss:CustomerCMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-03-31 0001597892 jrss:CustomerMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-03-31 0001597892 jrss:CustomerMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-03-31 0001597892 jrss:CustomerAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-03-31 0001597892 jrss:CustomerAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-03-31 0001597892 jrss:CustomerMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-03-31 0001597892 jrss:CustomerMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-03-31 0001597892 jrss:VendorAMember us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2024-01-01 2024-03-31 0001597892 jrss:VendorAMember us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2024-03-31 0001597892 jrss:VendorBMember us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2024-01-01 2024-03-31 0001597892 jrss:VendorBMember us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2024-03-31 0001597892 jrss:VendorCMember us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2024-01-01 2024-03-31 0001597892 jrss:VendorCMember us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2024-03-31 0001597892 jrss:VendorMember us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2024-01-01 2024-03-31 0001597892 jrss:VendorAMember us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2023-01-01 2023-03-31 0001597892 jrss:VendorAMember us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2023-03-31 0001597892 jrss:VendorBMember us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2023-01-01 2023-03-31 0001597892 jrss:VendorBMember us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2023-03-31 0001597892 jrss:VendorMember us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2023-01-01 2023-03-31 0001597892 jrss:VendorMember us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2023-03-31 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure iso4217:CNY

JRSIS HEALTH CARE Corp 10-Q